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Type 2 diabetes mellitus (T2DM) is a complex and common disease (approximate 
90-95% of all cases of DM diagnosed) and the prevalence is increasing at a shocking 
rate. In this study, we used isolated pancreatic islets P-cells of obese/diabetic 
�db”db+�mice , as our animal model for human T2DM which exhibit phenotypes of 
human T2DM, and its normal littermate (lean/non-diabetic (db^/rn^) mice) to 
evaluate the underlying mechanisms involved in pancreatic islets dysfunction and the 
possible beneficial effects provided by N-acetyl-L-cysteine (L-NAC, a common 
anti-oxidant) on the restoration of the blunted glucose-induced insulin release. Our 
results demonstrate that glucose (5 and 15 mM)-induced insulin release and insulin 
content of isolated pancreatic islets p-cells of obese/diabetic ( d b V d b � m i c e was 
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much lower compared to isolated pancreatic islets P-cells of lean/non-diabetic 
(db^/m^) mice. On the other hand, the level of mitochondrial reactive oxygen species 
(ROS) measured in single pancreatic islets P-cells of obese/diabetic { dbVdb�m i ce 
was higher under the basal conditions (5 mM glucose in the medium) as well as in 
response to elevated glucose (15 mM) challenge, compared to that observed in single 
pancreatic islets P-cells of lean/non-diabetic (db^/m^) mice. L-NAC (20 mM, 24 hr 
incubation) markedly suppressed mitochondrial ROS generation of single pancreatic 
islets P-cells of both strains of mice, in response to elevated glucose (15 mM) 
challenge. The attenuated mitochondrial ROS generation caused by L-NAC 
incubation was associated with the restoration of the blunted glucose-induced insulin 
release and an increase of insulin content of isolated pancreatic islets of 
obese/diabetic {db^/db^) mice. In addition to mitochondrial ROS generation, F-actin 
cytoskeleton levels of single pancreatic islets P-cells of lean/non-diabetic (J办+/m+) 
mice and obese/diabetic (db^/db^) mice, before and after L-NAC treatments, were 
estimated. Our results illustrate that a higher level of F-actin cytoskeleton (F-actin 
cytoskeleton polymerization) was detected in single pancreatic islets p-cells of 
obese/diabetic { d b ” d b � m i c e , compared to that observed in lean/non-diabetic 
{db^/m^) mice. Moreover, single pancreatic islets P-cells of lean/non-diabetic 
{db^/rn') mice bathed in elevated glucose medium (24 hr) resulted in an increase in 
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F-actin cytoskeleton levels. However, no apparent change in F-actin cytoskeleton 
levels was observed in isolated pancreatic islets P-cells of obese/diabetic (db^/db'^) 
mice bathed in elevated glucose medium. Interestingly, L-NAC incubation markedly 
attenuated the elevated F-actin cytoskeleton levels in isolated pancreatic islets p-cells 
of obese/diabetic {db+/db+�mice (bathed in normal and elevated glucose medium), 
and in isolated pancreatic islets P-cells of lean/non-diabetic {db'^/m^) mice bathed in 
elevated glucose medium. 
Thapsigargin (a commonly-used oxidative stress inducer) pre-treatment (0.5 fiM, 
24-hr) resulted in an elevation of mitochondrial ROS generation of single pancreatic 
islets P-cells of obese/diabetic {db今/db+�mice and lean/non-diabet ic�dbVm�mice 
irrespective of the glucose levels in the medium. In addition, a blunted 
glucose-induced insulin release and insulin content of isolated pancreatic islets of 
obese/diabetic { d b V d b � m i c e and lean/non-diabetic�dbVm+�mice was observed. 
Co-incubation with L-NAC, the elevated mitochondrial ROS level by thapsigargin 
was reduced and the blunted glucose-induced insulin release was restored. 
Pre-treatment with H2O2 (a common ROS) markedly enhanced the mitochondrial 
ROS levels in single pancreatic islets P-cells of both non-diabetic/lean {db+/m+�and 
obese/diabetic { d b V d b � m i c e in response to high glucose (15 mM) stimulation. On 
the other hand, in normal glucose (5 mM) medium, a higher level of ROS was only 
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detected in single pancreatic islets P-cells of diabetic {dbVdb+�mice but not in single 
pancreatic islets p-cells of non-diabetic/lean {dbVm女、mice. Pre-treatment with 
L-NAC resulted in the amelioration of H202-mediated mitochondrial ROS 
generation. 
DL-Buthionine-[S,R]-Sulfoximine (BSO) (an oxidative stress inducer and an 
irreversible inhibitor of y-glutamylcysteine synthetase (y-GCS) (an important 
enzyme involved in cellular glutathione synthesis) treatments markedly reduced 
glucose-induced insulin release and insulin content of isolated pancreatic islets 
P-cells of lean/non-diabetic {db^/rn^) mice whereas there was no apparent change in 
obese/diabetic (db^'/db^) mice. Moreover, BSO pre-treatment resulted in a 
significantly higher mitochondrial ROS levels measured in single pancreatic islets 
P-cells of lean/non-diabetic (db^/m^) and obese/diabetic (db^/db^) mice bathed in 
normal glucose (5 mM) medium and elevated glucose (15 mM) medium. 
Co-incubation with L-NAC successfully reduced BSO-induced elevated 
mitochondrial ROS generation and restored the blunted glucose-induced insulin 
release/insulin content. 
4-Phenyl butyric acid (4-PBA) and ursodeoxycholic acid (UA) (chemical chaperones 
which abolish oxidative damage within the cells) treatments resulted in attenuation of 
the basal mitochondrial ROS levels in the pancreatic p-cells of both 
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lean/non-diabetic {db^/nC) and diabetic { d b V d b � m i c e under the basal glucose 
conditions. In addition, 4-PBA enhanced both glucose-induced insulin secretion and 
insulin content in single pancreatic islets P-cells of diabetic {db^/db^) mice whereas 
UA only improved the insulin content but not glucose-induced insulin secretion, in 
pancreatic p-cells of diabetic (dh^/db^) mice. 
Cytochalasin B (F-actin depolymerisation inducer) treatment enhanced whereas 
jasplakinolide (F-actin polymerization inducer) inhibited glucose-induced insulin 
release and insulin content of isolated pancreatic islets of lean/non-diabetic (db+/m+� 
mice. Moreover, cytochalasin B markedly reduced whereas jasplakinolide enhanced 
mitochondrial ROS generation and F-actin cytoskeleton levels in single pancreatic 
islets p-cells of obese/diabetic (dbVdb^�and lean/non-diabetic {db^/m^) mice. 
Effects of jasplakinolide were ameliorated by L-NAC co-treatment. 
In conclusion, our results demonstrate, for the first time, that L-NAC (an anti-oxidant) 
treatment provide protective effects (i.e. restoration of the blunted glucose-induced 
insulin release plus the reduced insulin content) against oxidative stress / insults in 
pancreatic islets P-cells of obese/diabetic {db^/db^) mice probably via inhibition of 
mitochondrial ROS generation (under basal conditions and in response to elevated 













含有5 mM的葡萄糖)以及對高濃度葡萄糖(15 mM)的反應下與瘦肉型/非糖尿病 
























度葡萄糖(15 mM)的剌激。本身在正常葡萄糖(5 mM)媒介，高水平的ROS只在 
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1. GENERAL INTRODUCTION 
1.1. Diabetes 
1.1.1. Overview 
The incidence of diabetes is increasing dramatically worldwide, especially in the 
developing countries such as India and China (Rolo et aL, 2006). Currently, the 
estimated prevalence of diabetes among adults was 5.9%, or 240 million people in 
the world (Codario, 2011). The prevalence of diabetes is expected to increase to 370 
million people by 2030 (Codario, 2011). The incidence of diabetes can be affected by 
age, ethnicity and weight status (Codario, 2011). Diabetes mellitus has been 
described as a metabolic disease associated with hyperglycaemia and insufficient 
insulin release (Rolo et aL, 2006). About 5-10% of all cases of diabetes represent 
type-1 diabetes mellitus (TIDM), which is characterised by autoimmune P-cell 
destruction with insulin deficiency and excessive loss of P-cells (Sivitz et aL, 2010). 
The most prevalent form of diabetes is type-2 diabetes mellitus (T2DM) 
(approximate 90-95% of all cases) (Sivitz et al., 2010). T2DM has been considered 
as a heterogeneous disease, which results from failure of insulin secretion associated 
with P-cell dysfunction and insulin resistance (Rolo et al., 2006). Most of the people 
affected by diabetes are at the middle age (45 - 64 years old); however, there are 
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about 30% of new cases with T2DM are children in the US (Rolo et ai, 2006). 
1.1.2. Diagnostic Criteria of Type-2 Diabetes 
Before the diagnostic criteria for diabetes mellitus has been published by the 
National Diabetes Data Group (NDDG) associated with World Health Organization 
(WHO) in 1979, diabetes was only classified as juvenile-onset diabetes, adult-onset 
diabetes, insulin-dependent diabetes or non-insulin-dependent diabetes (Leu & 
Zonszein, 2010). The terms TIDM and T2DM have been currently used to replace 
the previous terminology and the term "pre-diabetes" has been introduced to define a 
situation of a group of individuals with impaired fasting glucose and/or impaired 
glucose tolerance (Leu & Zonszein, 2010). Their blood glucose levels are higher than 
normal, but do not meet the diagnostic criteria for diabetes (Leu & Zonszein, 2010). 
The following are the general diagnostic criteria for diabetes (American Diabetes 
Association, 2004): 
1. Fasting glucose level > 7.0 mmol/L or 
2. Blood glucose level > 11.1 mmol/L after 75 g oral glucose intake in 2 hours or 
3. Random glucose level > 11.1 mmol/L or 
4. Haemoglobin Al-C (HbAlC) > 6.5% 
As diabetes is a complex metabolic disease which also links with other 
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life-threatening diseases such as premature cardiovascular disease, vascular disease 
and renal failure; the diagnostic criteria for diabetes are well-established and allow 
earlier diagnosis (Leu & Zonszein, 2010). 
1.1.3. Type-2 Diabetes (T2DM) 
As mentioned above, T2DM is a heterogeneous, complex and common disease, 
which affects about 100 million people worldwide and the prevalence is increasing at 
a shocking rate (Fonseca et al., 2009). T2DM is characterised by impaired insulin 
secretion/synthesis, insulin resistance, p-cells dysfunction and reduction of P-cell 
mass (Codario, 2011). 
1.1.3.1. Impaired Insulin Synthesis and Insulin Secretory Defects in Type-2 
Diabetes 
Approximately two million clusters of cells constitute the islets of Langerhans in the 
endocrine pancreas, which include at least four cell types: alpha cells (a-cells), beta 
cells (p-cells), delta cells (6-cells) and pancreatic polypeptide (PP) cells (Wierup et 
al., 2002). p-cells are nearly 65 - 80% of total islet cells and they are centrally 
distributed within the islets for insulin synthesis and secretion (Brass et al., 2010). 
Pre-proinsulin in the rough endoplasmic reticulum of P-cells is readily converted to 
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proinsulin via the trans-Go\g\ network and packed into clathrin-coated vesicles 
(Brass et al., 2010). These proinsulin-containing vesicles can be further converted to 
insulin and to be released from vesicles upon the stimuli, such as an ingested meal or 
glucose administration (Brass et al., 2010). 
The insulin response is always biphasic in normal subjects. The first phase is rapid 
with a sharp peak, which lasts for less than 10 minutes; the second phase is constant, 
prolonged plateau, which lasts for the whole elevated blood glucose period (Fonseca 
et al., 2009). The first phase demonstrates the insulin release from a cluster of 
secretory vesicles which are docked at the cell membrane and ready for the calcium 
signal and the second phase represents the refill of insulin-containing secretory 
vesicles for immediate release (Brass et al., 2010). 
However, the insulin secretory capacity and the p-cell sensitivity to glucose are 
usually reduced in patients with T2DM (Fonseca et al, 2009). The first phase of 
glucose-induced insulin secretion is lost and the proinsulin together with its split 
products are secreted along with insulin in patients with T2DM (Fonseca et al., 2009). 
During the late stage of T2DM, the pancreatic p-cell mass is gradually decreased as 
p-cell death causing marked reduction of insulin secretion (Fonseca et al., 2009). 
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1.1.3.2. p-Cell Dysfunction 
It is generally accepted that there is a progressive decline in p-cell functions over 
time in T2DM independent of the type of treatments (Wajchenberg, 2007). The 
number of p-cells is gradually decreased by 20 — 50% and the remaining P-cells are 
also deteriorated in patients with long-term T2DM (Fonseca et al., 2009; Porte et aL, 
2001; Wajchenberg, 2007). These usually happen from the compensation for insulin 
resistance in the majority of patients with impaired glucose tolerance (Wajchenberg, 
2007). The defect in p-cell glucose homeostasis, deficiency of the key stimulatory 
molecule, p-cell apoptosis due to prolonged hyperglycemia, oxidative stress and 
amyloid deposition contribute to the causes of P-cell dysfunction in T2DM (Fonseca 
et al, 2009). Obviously, the reduction of P-cell mass diminishes the insulin secretion 
in T2DM (Wajchenberg, 2007). 
1.1.3.3. Insulin Resistance 
Insulin resistance is one of the major defects contributing to progressive 
hyperglycemia in patients with T2DM. It is usually connected with obesity and 
physical inactivity (Herzlinger & Abrahamson, 2010). Insulin resistance starts from a 
decrease in insulin sensitivity causing the compensation of insulin by extra insulin 
synthesis and secretion for maintaining the normal glucose level (Ferrannini et aL, 
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1998; Fonseca et al., 2009). At the early stage of T2DM, the patients are 
hyperinsulinemic rather than hyperglycemic (Groop, 1999). This insulin 
compensatory mechanism collapses over time in patients with long-standing T2DM 
(Fonseca et al., 2009). The glucose uptake in peripheral tissue (such as skeletal 
muscle, adipose tissue and liver) is gradually impaired in patients with insulin 
resistance, causing hepatic glucose over-production (DeFronzo, 1988). Since the 
inhibitory effect of insulin declines for suppressing gluconeogenesis in the liver, the 
basal hepatic glucose output can be increased. The hepatic glucose over-production is 
one of the main causes of fasting and postprandial hyperglycemia (Fonseca et al., 
2009). It is well known that hyperglycemia leads to glucotoxicity, which contributes 
to p-cell dysfunction (Fonseca et al., 2009). Insulin resistance can also be caused by 
the decrease in the insulin receptor number. Fewer insulin receptors have been 
detected on the insulin target tissues in the subjects with impaired glucose tolerance 
and obese, leading to insulin insensitivity (Kolterman et al., 1981). 
1.1.4. Glucose Toxicity 
Glucotoxicity is defined as non-physiological and irreversible P-cell damage caused 
by chronic exposure of high glucose (Eizirik et al, 2008). Inositol Requiring 1 (IREl) 
signalling pathway is activated by high glucose to regulate pro-insulin biosynthesis 
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in pancreatic P-cells (Lipson et al., 2006). However, both of the endoplasmic 
reticulum (ER) stress and hyper-activation of IRE 1 signalling pathway are caused by 
glucose toxicity, leading to the suppression of insulin gene expression (Lipson et aL, 
2006). As a result, the reduction of insulin gene expression further leads to the 
decreases in insulin synthesis and secretion (Wajchenberg, 2007). The development 
of many metabolic abnormalities and diseases such as T2DM, hypertension, 
cardiovascular diseases and kidney diseases are contributed by the effects of insulin 
resistance including chronic hyperglycemia and hyperinsulinemia (Busija et al., 
2006). With those diseases, the levels of glucose and free fatty acids in the blood are 
increased and the oxidative stress in exposed cells and tissues is also increased 
(Newsholme et al., 2007). Hyperglycemia induces the production of harmful free 
radicals enhancing oxidative stress through both enzymatic and non-enzymatic 
reactions (Codario. 2011). These free radicals contain at least one unpaired electron, 
so that they are readily combine with hydrogen and form toxic hydroxyl radicals. 
These toxic hydroxyl radicals damage the cells directly by causing oxidation in 
mitochondrial DNA, lipids, proteins and cellular structures (Narayan et al., 2003). 
Oxidative damage in pancreatic P-cells involves the activation of hexosamine 
pathway, which increases intracellular reactive oxygen species (ROS) levels (mainly 
hydrogen peroxide) leading to impaired insulin secretion and insulin resistance, 
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resulting in P-cell dysfunction (Goldstein, 2002). 
1.1.4.1. Fasting Hyperglycemia 
Fasting hyperglycemia is very common in T2DM. Impaired insulin secretion and 
insulin resistance cause impairment of insulin-mediated glucose uptake in skeletal 
muscle. Thus, more glucose remains in the circulation, resulting in the rise of fasting 
glucose level and glucose disposal (urinary glucose loss) (Fonseca et al., 2009). 
1.1.4.2. Postprandial Hyperglycemia 
Due to the impaired suppression of hepatic glucose output (HGO) after meals in the 
diabetic state, the ingested glucose mainly enters the systemic circulation. Also, the 
muscle insulin resistance and impaired insulin secretion contribute to the deficiency 
of glucose removal. Therefore, the plasma glucose level increases substantially. This 
condition in T2DM is referred as postprandial hyperglycemia (Fonseca et al., 2009). 
1.2. Oxidative Stress 
1.2.1. ROS and Mitochondria 
Excessive production of ROS such as superoxide (O2'), the precursor of ROS, 
hydroxyl radical (OH ) and the uncharged species hydrogen peroxide (H2O2) are 
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referred as the oxidative stress (Li et al., 2008). Generally, ROS are the by-products 
during respiration in mitochondria. ROS have an important role in many biological 
responses such as mitochondrial uncoupling and cell signalling but ROS also have 
harmful effects, such as impairing the insulin synthesis and causing P-cell 
dysfunction and P-cell apoptosis (Li et al., 2008). In most cells, mitochondria are the 
main source of ROS under non-stress conditions and therefore, they become the 
primary target of oxidative damage (Pi et al., 2010). Superoxide (O2.-) is a very 
reactive molecule and it is mainly generated in the inner mitochondrial membrane 
which are the NADH dehydrogenase at complex I and the interface between 
ubiquinone and complex III (Li et al., 2008). Superoxide can be converted by 
superoxide dismutase (SOD) into less reactive, uncharged, freely diffusible H2O2, 
which can be degraded rapidly into non-toxic products, oxygen and water, by 
catalase, glutathione peroxidase (GPx) and peroxiredoxin (Prx) (Pi et al, 2010). 
1.2.2. ROS Production by Mitochondria 
High concentration of glucose (hyperglycaemia) induces ROS generation during 
glucose metabolism via a variety of mechanisms including oxidative phosphorylation, 
glucose auto-oxidation, protein kinase C (PKC) activation and methylglyoxal 
formation (Pi et al., 2010). Excessive ROS generation leading to oxidative stress is a 
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key factor in the development and progression in the pathogenesis of diabetes and its 
complications due to overproduction of free radicals and impaired endogenous 
antioxidant defence systems (Newsholme et al., 2007). The cellular energy is 
generated as electrons in the mitochondria through various redox carriers of electron 
transport chain (ETC), which is formed with complexes I, II, III, IV and V (Sivitz et 
al., 2010). The product from glycolysis, pyruvate, is oxidised to generate NADH for 
electron entry at complex I by tricarboxylic acid (TCA) cycle; while the electrons are 
generated via succinate conversion to fumarate at complex II (Sivitz et al., 2010). 
The electrons from the entry sites direct flow through ubiquinone at complex III and 
are transferred to cytochrome c, a mobile intermediate at complex IV (Sivitz et al, 
2010). Complex V is a joined membrane with Fo-ATPase and rotatory Fi-ATPase; 
therefore, it is also called ATP synthase (FoFi-ATPase) (Sivitz et al., 2010). Complex 
I and III have been suggested as the major sites of superoxide generation in 
mitochondria (Sivitz et al., 2010). Complex I likely generates superoxide to the 
matrix side of the inner mitochondrial membrane, while the superoxide is released by 
complex III to both the matrix side and the outward of inner mitochondrial 
membrane and extramitochondrial space (Sivitz et al, 2010). 
A proton (voltage) gradient is generated by the electron transfer through the 
mitochondrial respiratory chain for ATP production (Rolo et al., 2006). This 
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electrochemical proton gradient has a regulatory role on the overall rate of the 
electron transfer in ETC (Rolo et al., 2006). The ROS generation is governed by the 
activity of respiratory chain complexes with the electrochemical potential difference 
(Rolo et al., 2006). During the state of hyperglycaemia, both of the transmembrane 
proton gradient (ApH) and hyperpolarisation of the membrane potential (A平m) 
inhibit the proton pumps to generate high electrochemical potential difference and 
thus, they prolong the life of ubisemiquinone (one of the superoxide-producing 
electron transport intermediates) and the ATP/ADP ratio is also increased (Rolo et al, 
2006). These cause an electron accumulation with coenzyme Q in complex III due to 
the partial inhibition of the electron transfer and accelerate the reduction of O2 (Rolo 
et al., 2006). As a result, more free radical superoxides are generated within the 
mitochondria (Rolo et al., 2006). Therefore, the changes in ApH and A^m can be 
concluded to modulate the ROS generation. 
1.2.3. The Relationship of Glucose Recognition by p-cells and Oxidative Stress 
Glucose equilibrates across the plasma membrane via specific transporters (GLUT 1 
and GLUT 2) of pancreatic P-cells and is phosphorylated by glucokinase or high-Km 
hexokinase IV, which controls the rate of glycolysis to generate pyruvate 
(Newsholme et al., 2007; Wollheim et al； 2002). The rate of glycolysis and the 
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production of pyruvate are controlled by the activities of glucose-6-phosphate, 
fructose-6-phosphate and fructose-1,6-diphosphate (Newsholme et al., 2007). 
Mitochondrial dysfunction has been demonstrated to reduce glucokinase (GCK) 
expression, leading to the decreased insulin secretion and P-cell apoptosis (Lee et al., 
2009). Thus, this decreased GCK expression causes the reduced interactions between 
GCK and mitochondria (Lee et al., 2009). The association of GCK is important in 
preventing p-cell apoptosis as the GCK binding to mitochondria affects Bax binding 
and releases cytochrome C into cytoplasm (Lee et al., 2009). 
If there is a mutation in the glucokinase gene, the blood glucose regulation would be 
affected by the decrease in glucose sensitivity and these are associated with Type 2 
diabetes and also a syndrome of persistent hyperinsulinaemic hypoglycaemia of 
infancy (Maechler, 2002). The glucokinase gene mutation suggested the key role of 
glucokinase determining the transport of intermediates for glycolysis (Maechler, 
2002). There are also some mitochondrial shuttles, such as glycerophophate and 
malate/aspartate shuttles, with a role in maintaining the high rate of glycolysis and 
allowing the cytosolic NADH reoxidation (Maechler, 2002). The blockade of these 
shuttles has been suggested with an inhibitory effect on the glucose-induced insulin 
secretion (Maechler, 2002). 
Pyruvate is generated as the substrate in the mitochondria for pyruvate 
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dehydrogenase and pyruvate carboxylase, which produces acetyl-CoA and 
oxaloacetate respectively (Wollheim et al., 2002). Pyruvate dehydrogenase and two 
TCA cycle enzymes (isocitrate dehydrogenase and a-ketoglutarate dehydrogenase) 
reinforce the generation of metabolic coupling factors by the activation of Ca^^ 
(Maechler, 2002). The activity of oxaloacetate is remarkably high in pancreatic 
P-cells; it enters the TCA cycle to initiate a series of reactions (as mentioned above) 
resulting in hyperpolarisation of A平m and ATP formation in mitochondria (Maechler, 
2002). The ATP formed in mitochondria is then transferred to the cytosol, leading to 
an enhanced ATP/ADP ratio in the cytoplasm (Newsholme et al., 2007). These 
promote the closure of the ATP-sensitive K+ channels (KATP channels) and the plasma 
membrane is depolarised (Newsholme et al, 2007). As a result, the influx of 
extracellular Ca^^ is stimulated by the opening of voltage-sensitive Ca^^ channels, 
causing the increase in cytosolic Ca^^ (Newsholme et al, 2007; Wollheim et al., 
2002). This increase in cytosolic Cd^^ further stimulates the inositol 
1,4,5-trisphosphate (IP3)-sensitive stores, which enables the P-cells to be responsive 
to the muscarinic and purinergic stimuli with mobilization of cytosolic Ca^^ 
(Tengholm et al., 2001). The rise of cytosolic C a � . is the main trigger for insulin 
exocytosis of the insulin secretory vesicles fusing with the plasma membrane 
(Maechler, 2002). In pancreatic P-cells, both the rise of cytosolic Ca]. and insulin 
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secretion stimulated by glucose are biphasic (including first transient phase and 
second sustained phase) (Maechler, 2002). 
As mentioned before, the continuous increase of the intracellular Ca^^ can stimulate 
the mitochondrial ROS generation. In addition, Ca^ "" can also enhance the ROS 
generation via PKC activation, which is NADPH oxidase-dependent (Newsholme et 
al., 2007). Consequently, the ROS generated by those routes can induce the oxidative 
stress and contribute to p-cell apoptosis (Newsholme et al., 2007). 
1.2.4. Important Roles of Glutathione in Pancreatic p-cells and Glutathione 
Synthesis 
Glutathione (GSH) is a low-molecular-weight thiol, which predominantly (85 — 90%) 
presents in the cytosol of animal cells (intracellular) (Wu et al, 2004). The rest (10 — 
150/0) remains in many organelles, such as mitochondria, nuclear matrix and 
peroxisomes (Lu, 2000; Wu et al., 2004). Extracellular GSH is relatively low in 
plasma, which is around 2 - 2 0 |amol/L (Griffith, 1999; Jones, 2002). As GSH 
contains cysteine residue, GSH can be readily oxidised non-enzymatically by ROS 
and other electrophilic substances to glutathione disulfide (GSSG) (Lu, 2000; Wu et 
al., 2004). Therefore, oxidative stress causes the loss of intracellular GSH and the 
[GSH]:[GSSG] ratio is commonly used as an indicator to determine the antioxidative 
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capacity of cells (Griffith, 1999; Jones, 2002; Lu, 2000; Wu et al, 2004). Pancreatic 
islets have relatively low intracellular GSH levels compared to other cell types, such 
as liver cells; this could explain that pancreatic islets are the primary target of 
oxidative stress (Robertson et al, 2004). 
In the process of GSH synthesis, glutamate, cysteine, and glycine are catalysed 
sequentially to GSH by two main cytosolic enzymes, y-glutamylcysteine synthetase 
(GCS) and GSH synthetase (Griffith, 1999; Wu et al., 2004). 
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Figure 1: The enzymatic process of glutathione synthesis. 7) y-glutamyl transpeptidase, 2) y-glutamyl 
cyclotransferase, 5) 5-oxoprolinase, 4) y-glutamyl-cysteine synthetase, 5) glutathione synthetase, 6) 
dipeptidase, 7) glutathione peroxidase, 8) glutathione reductase, 9) superoxide dismutase, JO) BCAA 
transaminase (cytosolic and mitochondrial), 77) glutaminase, 12) glutamate dehydrogenase, 75) 
glutamine:fructose-6-phosphate transaminase (cytosolic), 14�nitric oxide synthase, 15) glutathione 
^'-transferase, 16) NAD(P)H oxidase and mitochondrial respiratory complexes, 17) glycolysis, 18) 
glutathione-dependent thioldisulfide or thioltransferase or nonenzymatic reaction, 19) transsulfiiration 
pathway, 20) deacylase, and 27) serine hydroxymethyltransferase. Abbreviations: AA, amino acids; 
BCKA, branched-chain a-ketoacids; GlcN-6-P, glucosamine-6-phosphate; GS-NO, glutathione-nitric 
oxide adduct; KG, a-ketoglutarate; L O O , lipid peroxyl radical; LOOK, lipid hydroperoxide; NAC, 
A^-acetylcysteine; OTC, L-2-oxothiazolidine-4-carboxylate; R., radicals; R, nonradicals; R-5-P, 
ribulose-5-phosphate; X, electrophilic xenobiotics (Wu et al., 2004). 
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As cysteine is readily catalysed to form GSH (see figure 1), GSH is the major 
transport form of cysteine and the intracellular pool of cysteine is relatively low 
(Lyons et al., 2000; Wu et al., 2004). GSH plays an important role in many cellular 
reactions. GSH acts as a scavenger for free radicals and ROS (including H2O2). GSH 
can be initiated by glutathione-S-transferase to form mercapturates with various 
electrophiles, physiological metabolites and xenobiotics (Fang et al., 2002; Wu et al., 
2004). Intracellular GSH regulates the uses of lipid, glucose and amino acid by 
conjugating with endogenous nitric oxide (NO) (Guarino et al, 2003). It also 
regulates cell proliferation and apoptosis. Furthermore, GSH can remove the toxic 
intracellular metabolites such as formaldehyde by converting it to 
S-formyl-glutathione (Townsend et al., 2003). 
1.2.5. N-acetyl-L-cysteine - A Potential Drug Treatment for Type-2 Diabetes? 
N-acetyl-L-cysteine (L-NAC) is an antioxidant which is commonly used in the 
management of paracetamol poisoning. Firstly, it has been clinically used as a 
mucolytics agent in 1960s (Meredith et al, 2006). L-NAC is capable to break the 
disulfide bonds and disrupt ionic binding of calcium of mucoproteins through its free 
sulfhydryl group (Spoerke & Rumack, 1995). L-NAC is able to protect the liver 
against pararcetamol-induced damage and reduce the mortality in patients via oral 
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and intravenous routes (Prescott et al., 1979; Smilkstein et al., 1988; Keays et al, 
1991). It has been also shown to be protective in animals against toxic substances 
such as heavy metals and alkylating agents (Flanagan, 1987). 
Pancreatic islets have the lowest intrinsic antioxidant capacity compared with other 
tissues and contain relatively low activities for major antioxidant enzymes (Cu/Zn 
SOD, Mn SOD and GPx) (Robertson et al., 2004). Thus, intake of cysteine supplier, 
L-NAC (also as a GSH precursor) has beneficial effects on pancreatic islets/p-cells 
by enhancing the GSH synthesis against oxidative stress (Lu, 2000; Wu et al., 2004). 
Besides, L-NAC has been also suggested to improve glucose-induced insulin 
secretion/synthesis (Lu, 2000; Robertson et al., 2004; Wu et al., 2004). However, 
there is very little evidence showing the underlying mechanism of the beneficial 
effects of L-NAC in primary pancreatic p-cells on T2DM. It has been studied for a 
long time, but L-NAC is still not introduced to be clinically used for T2DM. 
1.3. Role of F-actin Cytoskeleton on Glucose-induced Insulin 
Secretion 
A dense cortical actin network is associated and located beneath cell membrane in 
pancreatic p-cells. This cortical actin network acts as a barrier for insulin granule 
docking and fusion to cell membrane. Therefore, disruption of this network enhances 
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insulin secretion (Thurmond et al., 2003). Also, this cortical actin network is the 
primary target of oxidative stress which contributes to cellular aging and apoptosis 
(Farah et al., 2007). F-actin cytoskeleton is highly dynamic, which can be readily 
reorganised in response to many growth factors and intrinsic signals (Ridley, 1999). 
Failure of insulin secretion has been reported to be related to F-actin cytoskeleton 
polymerization. Glucose stimulation triggers transient F-actin remodelling to allow 
insulin-containing granules access to plasma membrane for subsequent docking, 
fusion and release, which are mediated by SNARE proteins (such as syntaxin-1 and 
VAMP-2) (see Fig. 2) and small Rho-family GTPases (Wang et al., 2009). The small 
GTPases are in either GTP- and GDP-bound forms which are around 20 to 30 kDa. 
They are involved in a superfamily consisting of Ras, Rho, Rab, Arf and Ran 
subfamilies (Kimura et al., 2011). 
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Figure 2: The F-actin cytoskeleton network during basal condition and glucose stimulation. (Left) 
F-actin cytoskeleton network is important for the transportation of insulin-containing granules and it 
acts as a barrier to prevent the formation of SNARE protein complex for insulin secretion. (Right) 
F-actin cytoskeleton depolymerisation is triggered by glucose stimulation to facilitate the docking, 
fusion of insulin-containing granules with the plasma membrane (PM), resulting in glucose-induced 
insulin secretion (Wang et al, 2009). 
The formation of microtubule network has been suggested to be induced by glucose 
and play an important role on the sustained second phase of insulin secretion 
(Farshori et al., 1994; Wang et al., 2009). This network in p-cells is essential for the 
transfer of insulin-containing granules from the cell interior to the active site near the 
plasma membrane (see Fig. 3) (Wang et al., 2009). The relationship of F-actin 
cytoskeleton and its associated proteins is well understood as regulating cellular 
functions in various cells, such as endothelial cells. However, it has not been well 
established in pancreatic p-cells at this stage (Kimura et al., 2011). 
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Figure 3: The F-actin cytoskeleton network involved in the first phase and second phase of insulin 
secretion. (1) The first phase of insulin secretion is triggered by the glucose metabolism. (2) F-actin 
cytoskeleton depolymerisation is induced by metabolic signal. (3) The insulin-containing granules are 
recruited and transported towards the plasma membrane (PM) for the second phase of insulin 
secretion. (Wang et al, 2009) 
1.4. Current Clinical Treatments for Type-2 Diabetes Mellitus 
Besides the insulin injection therapy, oral drug treatment is the major therapy for 
T2DM. Although lifestyle modification is essential and more appropriate for the 
treatment of early T2DM, oral anti-diabetic drug treatment is also recommended at 
the same time for glycemic control. The initial choice of therapy is metformin 
(Bailey et al., 1996) and the next choice is sulfonylureas (Rosenstock et al., 1996). 
However, these two drugs are not suitable for elderly patients and patients with 
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impaired renal function as they may cause serious side effects (Herzlinger & 
Abrahamson, 2010). Therefore, other drugs such as thiazolidinediones, 
a-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors or 
non-sulfonylurea secretagogues will be applied instead for targeting some defects in 
diabetes (Raz et al., 2006). 
1.4.1. Metformin 
Metformin is the only member in the class of biguanide. Metformin enhances insulin 
sensitivity and decreases insulin resistance by improving glucose uptake in muscle 
and fat. It can also inhibit the glycogenolysis and hepatic gluconeogenesis as its 
principal site of action is the liver (Codario, 2011; Inzucchi, 2002; Herzlinger & 
Abrahamson, 2010). However, metformin causes some side effects, such as 
gastrointestinal adverse effects, anorexia, nausea, diarrhoea, vomiting, metallic taste 
and lactic acidosis (rare) (Inzucchi, 2002; H e r z l i n g e r & Abrahamson, 2010). 
1.4.2. Sulfonylureas 
Glimepiride, glyburide and glipizide are available as a class of drug called 
sulfonylureas (SUs), which are commonly prescribed for enhancing insulin secretion 
(basal insulin production) by closing the adenosine triphosphate (ATP)-dependent 
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potassium (KATP) channel in the plasma membrane of pancreatic P-cells (Herzlinger 
& Abrahamson, 2010). The common side effects of SUs are weight gain and 
hypoglycaemia (Herzlinger & Abrahamson, 2010). 
1.4.3. Thiazolidinediones 
Thiazolidinediones (TZDs) include rosiglitazone and pioglitazone, which are the first 
line drugs for targeting insulin resistance in diabetic patients. TZDs principally work 
by enhancing insulin sensitivity by suppressing hepatic gluconeogenesis mediated 
through peroxisome proliferator-activated receptors (PPARs) (Herzlinger & 
Abrahamson, 2010). Weight gain has been suggested as a significant side effect of 
TZDS. Other side effects include edema, anemia, liver toxicity and increased 
potential for the development of congestive heart failure (Fonseca, 2003). 
1.4.4. Glinides (Meglitinide Analogues) 
Glinides are non-sulfonylurea secretagogues for improving the early-phase insulin 
response. Therefore, the insulin levels between meals can be returned to baseline 
(Gerich, 1997). The common side effects are hypoglycaemia and weight gain 
(Herzlinger & Abmhamson, 2010). 
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1.4.5. a-Glucosidase (AG) Inhibitors 
There are two available AG inhibitors, called ascarbose and miglitol. They inhibit 
a-glucosidase resulting in delay absorption of carbohydrates in the mid- and distal 
intestine and compensating for impaired early phase insulin response (Chiasson et al., 
1994). They have relatively less side effects, most likely gastrointestinal (GI) adverse 
effects. 
1.4.6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 
DPP-4 inhibitors are the attractive oral therapy for diabetes. They slow the 
degradation of glucagon-like peptide (GLP-1) by inhibiting DPP-4. They are capable 
to suppress the glucagon release and increase glucose-induced insulin secretion. 
DPP-4 inhibitors uses do not associate with weight gain/loss and they rarely cause 
serious side effects, thus, they are now commonly use in combination with TZDs, 
SUs and metformin (Amori et al., 2007; Balas et al., 2007). 
1.4.7. (Clinical) Antioxidant Treatment 
Many antioxidative substances have been suggested to have beneficial effects on 
diabetes in animal studies, but only taurine has been introduced to be clinically used. 
Taurine has been demonstrated to be useful as a supplement in diabetes, mainly by its 
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antioxidant and anti-inflammatory effects (Schaffer et al., 2009; Suzuki et al, 2001; 
Szymanski et al., 2008). Taurine are beneficial by inhibiting ROS generation (not as 
ROS scavenger) and participating in formation of bile-acid conjugates in patients 
with TIDM and T2DM (Schaffer et al., 2009). Taurine are used for clinical 
complications of diabetes, which are nephropathy, retinopathy, platelet aggregation 
and cardiovascular complications (De la Puerta et al., 2010). 
1.5. Animal Models Used in Type-2 Diabetes Research 
The inbred mouse strain (C57BL/KsJ) non-diabetic {db^/rn^) and genetically diabetic 
(db^/db^) mice were used as the animal models in this study. The mutation diabetes 
occurred in the (dbVdb—�mice which are originated at Jackson Laboratory (Bar 
Harbor, ME, USA) with metabolic syndrome resembling human T2DM (Coleman, 
1978). The characteristics of the diabetic {db^/db^) mice are non-fertile, fat, 
hyperglycemic, spontaneously hyperphagic, hyperinsulinemic and insulin resistant 
(Coleman, 1978; Hummel et al., 1966). During the first 3 to 4 weeks, the deposition 
of fat in axillary and inguinal regions of the diabetic {dbVdb+�mice was noticeable 
and their body weights rapidly increased (Hummel et al., 1966). However, this strain 
of mice exhibits ketosis, the loss of pancreatic P-cells, body weight loss and 
nephropathy at older ages (Coleman, 1978). The blood glucose level of 
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non-diabetic/control {db^/m") mice was equal or less than 200 mg/100 ml at any age, 
while the blood glucose level of diabetic (db^/db^) mice was around 300 mg/100 ml 
at 10 weeks of age (Hummel et al., 1966). 
The diabetic (db^/db^) mice also exhibit the phenotypes of obesity, which causes 
abnormal dietary habits such as hyperphagia resulting in complex phenotypes of 
T2DM (Herberg et al., 1977). They are widely accepted and used as a good model 
for T2DM, because both hepatic and peripheral insulin resistance have been observed 
(Hashimoto et al., 1996; Lam et al., 2006). 
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1.6. Aims of Study 
High concentration of glucose induces ROS generation during glucose metabolism 
via a variety of mechanisms including oxidative phosphorylation, glucose 
auto-oxidation, protein kinase C activation and methylglyoxal formation. Excessive 
ROS generation leading to oxidative stress is a key factor in the development and 
progression in the pathogenesis of diabetes. Failure of insulin secretion has been 
suggested to be related to the F-actin cytoskeleton polymerization and this F-actin 
cytoskeleton network is the primary target of oxidative stress. Chronic 
hyperglycemia contributes to glucose toxicity, which subsequently causes pancreatic 
P-cell loss/dysfunction, impaired insulin release/synthesis and insulin resistance. 
These defects are the characteristics of T2DM. L-NAC has been reported to have 
beneficial effects on oxidative stress and it also acts as a GSH precursor. However, 
there is very little evidence showing the underlying mechanism of the beneficial 
effects of L-NAC in primary pancreatic P-cells on T2DM. Therefore, this study 
aimed to investigate the protective mechanism(s) underlying the in vitro beneficial 
effects of L-NAC in response to high glucose stimulation on mitochondrial ROS 
generation (oxidative stress), cortical F-actin cytoskeleton dynamics and insulin 
secretion/synthesis in the pancreatic islets/p-cells. 
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2. RESEARCH DESIGN & METHODS 
2.1. Materials 
5 ml syringe Temmo 
PrecisionGlide™ Needle (30G x 1/2) BD 
Table 1. Sources and concentrations of drugs tested in this study: 
Drug Concentration Stock vehicle Source 
used 
N-acetyl-L-cysteine 20 mM Distilled water Sigma-Aldrich 
(anti-oxidant) 
Hydrogen Peroxide (ROS) 200 [xM Distilled water Sigma-Aldrich 
Jasplakinolide (actin 5 |iM DMSO Merck 
polymerisation inducer) 
Thapsigargin (oxidative 0.5 |aM DMSO Alomone Labs Ltd 
stress inducer) 
Cytochalasin B (actin 10 |iM Ethanol Acros Organics 
depolymerisation inducer) 
4-Phenylbutyric acid 1 mM Distilled water Acros Organics 
(Oxidative stress reducer) 
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Ursodeoxycholic acid 500 |ig/ml Distilled water Acros Organics 
(Oxidative stress reducer) 




RPMI 1640 medium: one packet of RPMI 1640 powder (Invitrogen, USA) was 
reconstituted with 1 L ddH20, and supplemented with 2.0 g NaHCOs (Sigma, USA). 
The medium was adjusted to pH 7.2 with 1 M HQ, filter sterilized to give a final pH 
of 7.4 and stored at 4�C. 
Complete RPMI 1640 medium: RPMI 1640 medium was supplemented with 10% 
foetal bovine serum (FBS) (Invitrogen, USA) and 1% antibiotic-antimycotic 
(Invitrogen, USA) prior to experiment and stored at 4�C. 
General Reagents 
Composition of Phosphate-Buffered Saline (PBS) 
Magnesium chloride.6H20 (MgCh) 0.495 mM 
Potassium chloride (KCl) 2.67 mM 
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Potassium Phosphate Monobasic (KH2PO4) 1.47 mM 
Sodium chloride (NaCl) 137.93 mM 
Sodium Phosphate Dibasic (Na2HP04.2H20) 8.1 mM 
Glycine 10 mM 
The solution was adjusted to pH 7.2 with 1 M HCl, filter sterilized to give a final pH 
of 7.4 and store at 4°C. 
All the above chemicals were purchased from Sigma-Aldrich (USA). 
Composition of Plain Kerbs-Ringer Bicarbonate Buffer (KRBB) 
Calcium chloride (CaCb) 1.8 mM 
Potassium chloride (KCl) 407 mM 
Potassium Phosphate Monobasic (KH2PO4) 1.2 mM 
Sodium chloride (NaCl) 120 mM 
HEPES 10 mM 
Sodium bicarbonate (NaHCOs) 25 mM 
Magnesium sulphate (MgS04) 1.2 mM 
The buffer was adjusted to pH 7.4 with 1 M NaOH and store at 4°C. 
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5 mM low glucose KRBB: 50 ml of plain KRBB was freshly supplemented prior the 
experiment with 0.1% bovine serum albumin Cohn V fraction (w/v) (Sigma, USA) 
and 0.045 g glucose (Sigma, USA). 
15 mM high glucose KRBB: 50 ml of plain KRBB was freshly supplemented prior 
the experiment with 0.1% bovine serum albumin Cohn V fraction (w/v) (Sigma, 
USA) and 0.135 g glucose (Sigma, USA). 
Triton X-100 (0.3%, v/v): This solution was prepared by mixing 0.3 ml of Triton 
X-100 with 99.7 ml of PBS and stored at 4°C. 
Paraformaldehyde (4%, w/v): This solution was prepared by dissolving 0.48 g of 
paraformaldehyde powder (Sigma, USA) in 8 ml of ddH^O with 80 of 1 M NaOH 
at 60�C. The solution was supplemented with 4 ml of 3X PBS and the pH was 
adjusted to pH 7.4 with 60 fil of 1 M HCl. Then, the solution was filter sterilized and 
cooled down to room temperature before use. 
2.2. Isolation of Islets of Langerhans and Single Pancreatic P-Cells 
C57BL/KsJ (female; 6 months old) non-diabetic (db+/m+�and genetically diabetic 
{db^/db'') mice were purchased from the Laboratory Animal Services Centre of the 
Chinese University of Hong Kong. The experimental procedures were approved by 
the Animal Experimentation Ethics Committee of the Chinese University of Hong 
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Kong (Ref. No. 04/054/MIS). The mice were killed by cervical dislocation and the 
pancreases were dissected out with the use of small scissors and fine forceps after 
ductal injection of 3 ml of collagenase P (2mg/ml) (Roche, Germany) dissolved in 
Hanks' Balanced Salt Solution (HBSS) (Invitrogen, USA). The perfused pancreases 
were incubated at 37®C for 5 min and they were then washed 3 times with HBSS. 
Pancreatic islets were then hand-picked under dissection microscope and incubated 
free-floating in Petri dishes containing the complete RPMI 1640 medium. 1 |il/ml of 
25X solution of protease inhibitor cocktail (Roche, Germany) was added to the 
cultured medium during the experiments. The isolated islets were used for mouse 
enzyme-link immunosorbent assay (ELISA) for insulin release. On the other hand, 
some pancreatic islets were further dissociated into single pancreatic P-cells by IX 
0.05% trypsin-EDTA (Invitrogen, USA) at 1>TC for 2 min and they were used for 
live cell confocal imaging for measuring the mitochondrial ROS levels and 
immunocytochemistry for measuring the cortical F-actin cytoskeleton levels (Please 
refer to section 2.3 and 2.4 for the detailed procedures). 
2.3. Measurement of Mitochondrial ROS Levels 
Isolated single pancreatic P-cells from both strains of mice were seeded on 
glass-bottom confocal culture dishes and cultured with low glucose (5 mM) complete 
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RPMI 1640 medium at 37°C in a 95% air and 5% CO2 atmosphere. They were 
assigned into two groups: control group without any drug treatment and drug treated 
group (see Table 1). To measure the mitochondrial ROS levels, enzymatic dissociated 
single pancreatic P-cells were incubated with the H^Oz-sensitive fluorescent probe -
Mitotracker Red reduced form (CM-H2XROS) (Invitrogen, USA) (2 |aM in 0.05% 
DMSO) for 1 hour in Leibovitz's L-15 medium (Invitrogen, USA). After 1 hour, cells 
were washed with Leibovitz's L-15 medium before commencing imaging. This 
fluorescent probe in reduced form does not fluorescence until it enters an actively 
respiring cell, in which it is oxidized to a fluorescent probe and selectively 
sequestered into the mitochondria (Imoto et al., 2006; Philipp et al., 2006). High 
glucose (15 mM) was added to the cells after 3 basal images were captured. Images 
of selected single pancreatic P-cells were captured at 8 s intervals for up to 20 min 
using an Eclipse CL Plus Confocal Microscope System (Nikon, Japan) and the 
fluorescence emission (MitoTracker Red: 579nm — 599nm) was guided through an 
oil-immersion objective (60x, numerical aperture 1.45). The fluorescent signal of 
single cells was detected as red fluorescent light using a xenon light source with 570 
nm barrier filter. Then the densities of the fluorescent signal were displayed using the 
computer software EZ-Cl 3.70 FreeViewer (Nikon, Japan). The densities of the 
fluorescent signal captured (equivalent to total mitochondrial ROS levels and 
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expressed as area under curve AUC) versus time were plotted using the computer 
software GraphPad Prism 5 (San Diego, USA) were plotted (Figs. 12A- 12E, 14A & 
14B). 
2.4. Measurement of Islets Insulin Release and Insulin Content 
Enzyme-link immunosorbent assay kit (ELISA) (Mercodia, Sweden) was used to 
measure the islet insulin release and insulin content under low glucose (5 mM) (basal 
secretion) and high glucose (15 mM) (stimulated secretion) conditions. 
2.4.1. Preparation of Samples 
Enzymatic dissociated pancreatic islets from both strains of mice were allocated into 
several groups: control group and the drug pre-treated groups with drugs as listed in 
Table 1. They were incubated free-floating in Petri dishes with low glucose (5 mM) 
complete RPMI 1640 medium for 24 hours at 37�C in a 95% air and 5% CO2 
atmosphere. All sample groups were then further separated into 10 islets per group 
and transferred to 24-well culture plate; each well contained 0.25 ml of either 5 mM 
low glucose KRBB or 15 mM high glucose KRBB. The islets were then incubated 
for 1 hour at 7>TC in a 95% air and 5% CO2 atmosphere. After incubation, 
supematants of each group were collected as releasable insulin samples and 
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acid-ethanol was added to the islet pellets for insulin content extraction. After 30-min 
incubation at room temperature, supematants of each group were collected as insulin 
content samples. 
2.4.2. Enzyme-Link Immunosorbent Assay (ELISA) 
Following the procedures of ELISA kit, 10 \il of samples and 100 |il of enzyme 
conjugate IX solution were added into each well of the mouse monoclonal 
anti-insulin coated 96-well plate and incubated on a plate shaker (700-900 rpm) for 2 
hours at room temperature. After 2-hour incubation, each well was washed 6 times 
with 700 1^1 of wash buffer IX solution. 200 [d of substrate TMB was added to each 
well and incubated for 15 min at room temperature. After 15 min, 50 of Stop 
solution was added to each well and the sample absorbance of each samples were 
read at 450 nm. The releasable insulin levels and insulin contents of the samples 
were calculated as ng/islet/hour. 
2.5. Immunocytochemistry 
Isolated single pancreatic P-cells from both strains of mice were seeded on glass 
coverslips cultured in 6-well plates. They were assigned into several groups: control 
group and the drug pre-treated groups with drugs as listed in Table 1. They were 
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incubated for 24 hours with either low glucose (5 mM) or high glucose (15 mM) 
complete RPMI 1640 medium at 37°C in a 95% air and 5% CO2 atmosphere. After 
24-hr incubation, cells were fixed with 4% paraformaldehyde for 20 min at room 
temperature and permeabilized with 0.3% Triton X-100 for 4 min at room 
temperature. After blocking with PBS and 0.5% BSA, cells were incubated for 30 
min with Alexa Fluor 488 phalloidin (5 U/ml) and 4 min with 0.2 fig/ml Hoechst 
33342 (both from Invitrogen, USA), subsequently rinsed and mounted under glass 
coverslips. They were then scanned under the confocal microscope for z-stacking 
(step size: 1 \xm) to give 3D images (Olympus FVIOO-ZCD laser confocal system, 
Japan). Then the intensities of the fluorescent signals versus frequencies curves were 
displayed by using the corresponding computer software Olympus FVIOOO. The 
intensities of the fluorescent signals versus frequencies curves were re-plotted by 
using the computer software GraphPad Prism 5 (San Diego, USA). In this software, 
the exact values of area under curve (AUG) were also analysed, which are equivalent 
to the total intensities of cortical F-actin cytoskeleton levels in the collection of 
whole cell 3D images and the bar charts (Figs. 16A-22B) were plotted. 
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2.6. Data and Statistical Analysis 
Results were analysed by using computer software GraphPad Prism 5 (San Diego, 
USA) and presented as means 土 S.E.M. Comparisons between the groups were 
performed using unpaired Student's t test or one-way ANOVA where appropriate, 
and the differences were considered significant at < 0.05. 
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3. RESULTS 
3.1. Effects of L-NAC, Various Oxidative Stress Inducers/Reducers 
and Actin Polymerisation/Depolymerisation Inducers on 
Releasable Insulin Levels and Insulin Contents in Response to 
Low Glucose (5 mM) and High Glucose (15 mM) of Isolated 
Pancreatic Islets of (db /m+) and (db+/db勺 Mice 
3.1.1. Effect of L-NAC on Insulin Secretion and Insulin Contents 
A significant lower level of insulin secretion was measured in the control (without 
drug pre-treatment) pancreatic islets of diabetic (dbVdb—�mice compared to that in 
the control pancreatic islets of non-diabetic (db^lrn) mice bathed in low glucose 
medium (5 mM) (0.364 士 0.007 versus 0.704 土 0.024 ng/islet/hour, P < 0.001) and 
high glucose medium (15 mM) (0.387 土 0.035 versus 0.902 土 0.085 ng/islet/hour, F 
< 0.01) respectively (Fig. 4A). 
L-NAC (20 mM, 24-hr pre-treatment) significantly increased the releasable insulin 
levels in the pancreatic islets of both non-diabetic {dbVm+�and iabetic (db^/db^) 
mice compared to the corresponding controls (by 2.7-fold, P < 0.05 and 3.2-fold, P < 
0.01 bathed in low glucose medium respectively; by 3.9-fold, P < 0.01 and 5.9-fold, 
户 < 0.01 bathed in high glucose medium respectively) (Fig. 4A). 
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On the other hand, a significant lower level of insulin contents was also measured in 
the control pancreatic islets of diabetic (db”db+�mice compared to that in the 
control pancreatic islets of non-diabetic {db^lrn^) mice bathed in low glucose medium 
(10.3 士 1.07 versus 34.2 ± 1.62 ng/islet/hour, F < 0.001) and high glucose medium 
(15.8 士 2.58 versus 37.8 土 7.43 ng/islet/hour, F < 0.05) respectively (Fig. 4B). 
L-NAC pre-treatment only increased the insulin contents significantly in the 
pancreatic islets of diabetic {db+/db+�mice bathed in low glucose and high glucose 
medium by 3.4-fold {P < 0.001) and 3.5-fold (P < 0.001) respectively (Fig. 4B), but 
not in the pancreatic islets of non-diabetic {db^lrn) mice. 
3.1.2. Effect of Cytochalasin B on Insulin Secretion and Insulin Contents 
As an actin depolymerisation inducer, cytochalasin B (10 |iM, 24-hr pre-treatment) 
significantly increased the releasable insulin levels in the pancreatic islets of both 
non-diabetic [db+/m+�and iabetic {db”db午、mice compared to the corresponding 
controls bathed in low glucose medium (by 53.9 ± 1.650/0, P < 0.001 and 131 土 
6.92%, P < 0.001 respectively) (Fig. 4A). However, it only increased the releasable 
insulin levels in the pancreatic islets of d iabet ic�db+/db+�mice bathed in high 
glucose medium by 89.8 土 2.11o/o (尸 < 0.01) (Fig. 4A). 
Similar to L-NAC, cytochalasin B pre-treatment only increased the insulin contents 
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significantly in the pancreatic islets of diabetic�db+/db+�mice bathed in low glucose 
and high glucose medium by 206 士 1.67o/o (P < 0.001) and 95.6 士 1.51o/o (P < 0.01) 



























































































































































































































































































































































































































































































































3.1.3. Effect of 4-Phenyl Butyric Acid on Insulin Secretion and Insulin Contents 
As an oxidative stress reducer, 4-phenyl butyric acid (4-PBA) (1 mM, 24-hr 
pre-treatment) significantly increased the releasable insulin levels in the pancreatic 
islets of both non-diabetic {db^/m") and diabet ic�dbVdb+�mice compared to the 
corresponding controls (by 140 ± 1.48o/o, P < 0.05 and 73.3 士 1.13%, P < 0.05 
respectively bathed in low glucose medium; by 201 ± 3.41o/o, P < 0.01 and 72.9 士 
2.88%, P < 0.05 respectively bathed in high glucose medium) (Fig. 5A). 
Similar to L-NAC, 4-PBA pre-treatment only increased the insulin contents 
significantly in the pancreatic islets of diabetic {db'^/db^) mice, but not in the 
pancreatic islets of non-diabetic {db^lrn) mice bathed in low glucose and high 
glucose medium by 138 土 3.06o/o (P < 0.01) and 75.6 土 1.79o/o (P < 0.05) 


































































































































































































































































































































































































































































































































3.1.4. Effect of Ursodeoxycholic Acid on Insulin Secretion and Insulin Contents 
Ursodeoxycholic acid (UA) (an oxidative stress reducer unlike L-NAC and 4-PBA) 
did not cause a significant change (P > 0.05) in insulin secretion in the pancreatic 
islets of both non-diabetic {db^/m^) and diabetic {db^/db^) mice bathed in low 
glucose and high glucose medium (Fig. 6A). Interestingly, UA pre-treatment 
increased the insulin contents significantly in the pancreatic islets of diabetic 
idb^/db'') mice bathed in low glucose and high glucose medium by 231 士 1.59o/o (P < 









































































































































































































































































































































































































































































































3.1.5. Effect of Hydrogen Peroxide on Insulin Secretion and Insulin Contents 
H2O2 is a common type of reactive oxygen species (ROS) which causes oxidative 
damage in cells. H2O2 (200 |aM, 24-hr pre-treatment) significantly reduced the 
releasable insulin levels in the pancreatic islets of diabetic (db^/db^) mice compared 
to the corresponding controls bathed in low glucose and high glucose medium by 
48.9 士 1.37o/o (P < 0.001) and 63.1 士 1.21o/o (F < 0.01) respectively. In contrast, the 
combined pre-treatment (24-hr) of H2O2 (200 [M) and L-NAC (20 mM) 
significantly increased the releasable insulin levels in the pancreatic islets of diabetic 
(db^/db^) mice compared to the corresponding H2O2 pre-treatment groups bathed in 
low glucose and high glucose medium by 4.1-fold {P < 0.01) and 4.0-fold (P < 0.01) 
respectively (Fig. 7A). 
H2O2 24-hr pre-treatment only significantly reduced the releasable insulin levels by 
39.5 士 1.21o/o (P < 0.05) in the pancreatic islets of non-diabetic�dbVm+�mice bathed 
in high glucose medium compared to the corresponding control. L-NAC significantly 
reversed H202-reduced releasable insulin level in the pancreatic islets of non-diabetic 
(db^/m^) mice bathed in high glucose medium by 3.5-fold {P < 0.01) (Fig. 7A). 
On the other hand, H2O2 (200 |aM, 24-hr pre-treatment) significantly reduced the 
insulin contents in the pancreatic islets of both non-diabetic (db"m+�and diabetic 
(db+/db+�mice compared to the corresponding controls (by 48.2 土 2.21o/o, P < 0.01 
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and 66.1 土 1.52o/o, P < 0.01 bathed in low glucose medium respectively; by 74.6 土 
1.47%, P < 0.05 and 88.8 土 1.47o/o, P < 0.01 bathed in high glucose medium 
respectively) (Fig. 7B). 
Interestingly, the combined pre-treatment of H2O2 and L-NAC significantly reversed 
H202-reduced insulin contents in the pancreatic islets of both non-diabetic {db^/m^) 
and diabetic (db^/db^) mice (by 1.9-fold, P < 0.05 and 3.0-fold, P < 0.05 bathed in 
low glucose medium respectively; by 3.4-fold, P < 0.01 and 6.9-fold, P < 0.01 













































































































































































































































































































































































































































































































































3.1.6. Effect of Jasplakinolide on Insulin Secretion and Insulin Contents 
Jasplakinolide (5 ^M, 24-hr pre-treatment) significantly reduced the releasable 
insulin levels in the pancreatic islets of non-diabetic (db+/m+) mice, but not in the 
pancreatic islets of diabetic (db^/db'') mice (P > 0.05), compared to the 
corresponding controls by 39.6 土 2.2% (P < 0.01) bathed in low glucose medium and 
53.7 土 l.2o/o (P < 0.01) high glucose medium respectively. The combined 
pre-treatment (24-hr) of jasplakinolide (5 |iM) and L-NAC (20 mM) significantly 
reversed the releasable insulin levels in the pancreatic islets of both non-diabetic 
(db^/m^) and diabetic {db'^/db^) mice compared to the corresponding jasplakinolide 
pre-treatment groups (by 11.5-fold, P < 0.001 and 3.3-fold, P < 0.05 bathed in low 
glucose medium respectively; by 9.6-fold, P < 0.001 and 2.4-fold, P < 0 . 0 1 bathed in 
high glucose medium respectively) (Fig. 8A). 
Jasplakinolide (5 |LIM, 24-hr pre-treatment) significantly reduced the insulin content 
by 59.4 士 1.6o/o {P < 0.001) in the pancreatic islets of non-diabetic (db”m+�mice 
bathed in low glucose medium only, but not in the pancreatic islets of diabetic 
(db^/db^) mice (P > 0.05) compared to the corresponding controls (Fig. 8B). 
Surprisingly, the combined pre-treatment (24-hr) of jasplakinolide (5 fiM) and 
L-NAC (20 mM) significantly reversed the insulin contents in the pancreatic islets of 
both non-diabetic ("广/m+) and diabetic ( d b ” d b � m i c e compared to the 
5 3 
corresponding jasplakinolide pre-treatment groups (by 1.8-fold, P < 0.05 and 
3.1-fold, P < 0.05 bathed in low glucose medium respectively; by 1.8-fold, P < 0.05 

























































































































































































































































































































































































































































































































































3.1.7. Effect of Thapsigargin on Insulin Secretion and Insulin Contents 
Thapsigargin (0.5 \xM, 24-hr pre-treatment) significantly reduced the releasable 
insulin levels in the pancreatic islets of both non-diabetic { d b ~ m � a n d diabetic 
(db^/db^) mice compared to the corresponding controls (by 37.3 土 1.250/0, P < 0.001 
and 27.7 土 1.62o/o, P < 0.001 bathed in low glucose medium respectively; by 51.5 土 
1.190/0, P < 0.01 and 30.2 土 1.19o/o, P < 0.05 bathed in high glucose medium 
respectively). The combined pre-treatment (24-hr) of thapsigargin (0.5 and 
L-NAC (20 mM) significantly reversed the releasable insulin levels in the pancreatic 
islets of both non-diabetic (db^/m^) and diabetic ( d b V d b � m i c e compared to the 
corresponding thapsigargin pre-treatment groups (by 5.9-fold, P < 0.01 and 2.2-fold, 
p < 0.001 bathed in low glucose medium respectively; by 5.5-fold, P < 0.05 and 
2.0-fold, P < 0.05 bathed in high glucose medium respectively) (Fig. 9A). 
Similarly, thapsigargin (0.5 |dM, 24-hr pre-treatment) significantly reduced the 
insulin contents in the pancreatic islets of both non-diabetic {db+/m�and diabetic 
{dh^/db^) mice compared to the corresponding controls (by 92 土 1.46o/o, P < 0.001 
and 73.7 ± 1.46%, P < 0.001 bathed in low glucose medium respectively; by 93.1 土 
1.46%, P < 0.01 and 83.1 士 1.46o/o, P < 0.05 bathed in high glucose medium 
respectively). The combined pre-treatment of thapsigargin (0.5 |aM) and L-NAC (20 
mM) significantly reversed the insulin contents in the pancreatic islets of both 
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non-diabetic (db^/m^) and diabetic (db+/db+�mice compared to the corresponding 
thapsigargin pre-treatment groups (by 10.7-fold, P < 0.001 and 2.4-fold, P < 0.01 
bathed in low glucose medium respectively; by 10.9-fold, P < 0.05 and 2.6-fold, P < 



































































































































































































































































































































































































































































































































































3.1.8. Effect of BSO on Insulin Secretion and Insulin Contents 
BSO (0.1 |aM, 24-hr pre-treatment) significantly reduced the releasable insulin levels 
in the pancreatic islets of diabetic idbVdb+�mice compared to the corresponding 
controls by 11 土 1.740/0 (P < 0.05) bathed in low glucose medium and 35.9 土 1.35o/o 
{P < 0.05) bathed in high glucose medium respectively. In contrast, BSO 
pre-treatment (24-hr) significantly reduced the releasable insulin levels in the 
pancreatic islets of non-diabetic (db^/m^) mice compared to the corresponding 
control by 39.2 土 1.25% (P < 0.05) bathed in high glucose medium only (Fig. lOA). 
The combined pre-treatment (24-hr) of BSO (0.1 |aM) and L-NAC (20 mM) 
significantly reversed the releasable insulin levels in the pancreatic islets of both 
non-diabetic (dbVm^�and diabetic (db^'/db'') mice compared to the corresponding 
BSO pre-treatment groups (by 2.3-fold, P < 0.001 and 1.3-fold, P < 0.01 bathed in 
low glucose medium respectively; by 2.0-fold, P < 0.01 and 1.4-fold, P < 0.05 
bathed in high glucose medium respectively) (Fig. lOA). 
BSO (0.1 laM, 24-hr pre-treatment) significantly reduced the insulin contents in the 
pancreatic islets of both non-diabetic {db^/m^) and diabetic {db,db+�mice compared 
to the corresponding controls (by 87.1 土 1.47o/o, P < 0.001 and 41.1 土 1.54o/o, P < 
0.05 bathed in low glucose medium respectively; by 82.8 土 1.47o/o, P < 0.05 and 62.9 
土 1.470/0, P < 0.05 bathed in high glucose medium respectively). The combined 
6 1 
pre-treatment (24-hr) of BSO (0.1 ^iM) and L-NAC (20 mM) significantly reversed 
the insulin contents in the pancreatic islets of both non-diabetic (db^/m^) and diabetic 
(db^/db^) mice compared to the corresponding BSO pre-treatment groups (by 
13.5-fold, P < 0.001 and 3.5-fold, P < 0.001 bathed in low glucose medium 
respectively; by 9.4-fold, P < 0.001 and 3.3-fold, P < 0.01 bathed in high glucose 






































































































































































































































































































































































































































































































































































3.2. Effects of L-NAC, Various Oxidative Stress Inducers/Reducers 
and Actin Polymerisation/Depolymerisation Inducers on 
Mitochondrial ROS Levels in Response to High Glucose (15 mM) 
Challenge in Isolated Single Pancreatic p-Cells o f � d b + l m � a n d 
(db”db"^ Mice 
3.2.1. Effects of L-NAC (20 mM), 4-Phenyl Butyric Acid (4-PBA) (1 mM), 
Ursodeoxycholic Acid (UA) (500 ^ig/ml), H2O2 (200 \iM), Thapsigargin 
(0.5 i^M) and DL-Buthionine-[S,R]-Sulfoximine (BSO) (0.1 ^M) 
Pre-treatments on Mitochondrial ROS Level in Response to High Glucose 
(15 mM) Challenge 
Higher basal mitochondrial ROS level was observed in single pancreatic p-cells of 
diabetic {db+/db+�mice (control) compared to single pancreatic P-cells of 
non-diabetic {db^/rn) mice (control) (Fig. 11). A significant higher mitochondrial 
ROS level was detected in single pancreatic p-cells of d i a b e t i c � d b " d b + � m i c e 
(control) (3.0-fold; P < 0.01) compared to single pancreatic P-cells of non-diabetic 
{db'^/m^) mice (control) in response to high glucose challenge (Fig. 12). 
After L-NAC (20 mM, 24-hr) pre-treatment, the mitochondrial ROS level in the 
single pancreatic p-cells of diabetic {db+/db+) mice was significantly reduced by 40.7 
土 0.87o/o (P < 0.01) compared to the corresponding control in response to high 
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glucose challenge, whereas there was no significant difference in the single 
pancreatic P-cells of non-diabetic (db^/m^) mice (Figs. 11 & 12). 
After 4-PBA (1 mM, 24-hr) pre-treatment, the mitochondrial ROS level in the single 
pancreatic P-cells of diabetic ( d b V d b � m i c e was significantly reduced by 53.6 土 
1.05% (P < 0.01) compared to the corresponding control in response to high glucose 
challenge, whereas there was no significant difference in the single pancreatic P-cells 
of non-diabetic {db”m+�mice (Figs. 11 & 12A). 
After UA (500 |ag/ml, 24-hr) pre-treatment, the mitochondrial ROS level in the single 
pancreatic P-cells of diabetic (db^/db^) mice was significantly reduced by 62 土 
1.05% (P < 0.01) compared to the corresponding control in response to high glucose 
challenge, whereas there was no significant difference in the single pancreatic P-cells 
of non-diabetic {db+/m+�mice (Figs. 11 & 12B). 
After H2O2 (200 |aM, 24-hr) pre-treatment, the mitochondrial ROS level in response 
to high glucose challenge in the single pancreatic P-cells of non-diabetic {db+/m+� 
mice was significantly increased by 2.6-fold (P < 0.01), whereas there was no 
significant difference in the single pancreatic p-cells of diabetic {db^/db^) mice. The 
combined pre-treatment (24-hr) of H2O2 (200 and L-NAC (20 mM) 
significantly reduced the mitochondrial ROS levels in the single pancreatic P-cells of 
both non-diabetic {dbVm'') and diabetic {dhVdb^) mice by 45.4 士 1.48o/o (P < 0.01) 
6 6 
and 37.8 士 1.92o/o (P < 0.05) respectively (Figs. 11 & 12C). 
After thapsigargin (0.5 |iM, 24-hr) pre-treatment, the mitochondrial ROS levels in 
response to high glucose challenge in the single pancreatic P-cells of both 
non-diabetic (db^/m^) and diabetic {db^/dh^) mice were significantly increased by 
3.5-fold (P < 0.001) and 3.0-fold {P < 0.001) respectively. The combined 
pre-treatment (24-hr) of thapsigargin (0.5 ^iM) and L-NAC (20 mM) significantly 
reduced the mitochondrial ROS levels in the single pancreatic P-cells of both 
non-diabetic {db”m女�and diabetic {dbVdb^) mice by 52.7 士 1.02o/o {P < 0.001) and 
82.2 土 1.120/0 (P < 0.001) respectively (Figs. 11 & 12D). 
After BSO (0.1 |LIM, 24-hr) pre-treatment, the mitochondrial ROS levels in response 
to high glucose challenge in the single pancreatic p-cells of both non-diabetic 
idb^/rn^) and diabetic�db+/db+�mice were significantly increased by 5.5-fold {P < 
0.001) and 2.1-fold (P < 0.05) respectively. The combined pre-treatment (24-hr) of 
BSO (0.1 |iM) and L-NAC (20 mM) significantly reduced the mitochondrial ROS 
levels in the single pancreatic p-cells of both non-diabetic ( db”m+�and diabetic 
(db^/db^) mice by 84.9 士 1.15o/o (P < 0.001) and 84.6 土 l.Oo/o (P < 0.01) respectively 
(Figs. 11 & 12E). 
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Figure 11: Representative live cell confocal microscopic images - mitochondrial 
ROS levels in single pancreatic P-cells of non-diabetic (db^/m^) and diabetic 
{db+ /db女、mice, in response to high glucose (15 mM) challenge, in the absence 
(control) or the presence of L-NAC (20 mM, 24-hr), 4-PBA (1 mM, 24-hr), UA (500 
|ag/ml, 24-hr), H2O2 (200 laM, 24-hr), thapsigargin (0.5 ^iM, 24-hr) and BSO (0.1 fiM, 
24-hr) pre-treatments. Mitochondrial ROS levels were estimated using reduced 
MitoTracker Red (CM-H2XROS) and visualized under confocal microscope (60X 
magnification). The images were taken at the mid-plane of cells. Scale bar: 5 jum or 
3 fjm. 
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Figure 12A: Mitochondrial ROS levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic (db+/m+�and diabetic 
{db^/db^) mice, in response to high glucose (15 mM), in the absence (control) or the 
presence of L-NAC (20 mM, 24-hr) or 4-PBA (1 mM, 24-hr) pre-treatment. Data are 
expressed as means 土 S.E.M. ** P <0.01 (n二3). 
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Figure 12B: Mitochondrial ROS levels (expressed as AUG (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic (db+/m+) and diabetic 
(dbVdb^�mice, in response to high glucose (15 mM), in the absence (control) or the 
presence 
of L-NAC (20 mM, 24-hr) or UA (500 |ag/ml, 24-hr) pre-treatment. Data 
are expressed as means 士 S.E.M. ** P <0.01 (n=3). 
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Figure 12C: Mitochondrial ROS levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic {db+ / m � a n d diabetic 
{db+/db+�mice, in response to high glucose (15 mM), in the absence (control) or the 
presence of L-NAC (20 mM, 24-hr) or H2O2 (200 |iM, 24-hr) pre-treatment. Data are 
expressed as means 士 S.E.M. * P < 0.05 and ** P <0.01 (n=3). 
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Figure 12D: Mitochondrial ROS levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic {db^/m^) and diabetic 
(db^/db^) mice, in response to high glucose (15 mM), in the absence (control) or the 
presence of L-NAC (20 mM, 24-hr) or thapsigargin (0.5 |aM, 24-hr) pre-treatment. 
Data are expressed as means 土 S.E.M. ** P <0.01 and *** P < 0.001 (n=3). 
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Figure 12E: Mitochondrial ROS levels (expressed as AUG (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic (db^/m^) and diabetic 
(db^/db^) mice, in response to high glucose (15 mM), in the absence (control) or the 
presence of L-NAC (20 mM, 24-hr) or DL-Buthionine-[S,R]-Sulfoximine (BSO) 
(0.1 |iM, 24-hr) pre-treatment. Data are expressed as means 土 S.E.M. * P < 0.05, ** 
P <0.01 and *** P < 0.001 (n=3). 
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3.2.2. Effects of L-NAC (20 mM), Cytochalasin B (10 i^M) and Jasplakinolide (5 
|xM) Pre-treatments on Mitochondrial ROS Level in Response to High 
Glucose (15 mM) Challenge 
As mentioned above in 3.2.1., L-NAC (20 mM, 24-hr pre-treatment) significantly 
reduced the mitochondrial ROS level in the single pancreatic P-cells of diabetic 
(db^/db^) mice by 40.7 ± O.870/0 (P < 0.01) compared to the corresponding control in 
response to high glucose challenge. Similarly, cytochalasin B (10 [iM, 24-hr 
pre-treatment) significantly reduced the mitochondrial ROS level in the single 
pancreatic P-cells of diabetic (db”db+�mice by 42.3 士 1.14o/o (P < 0.05) compared to 
the corresponding control in response to high glucose challenge, whereas there was 
no significant difference in the single pancreatic P-cells of non-diabetic { d b V m � 
mice (Figs. 13 & 14A). 
After jasplakinolide (5 [M, 24-hr) pre-treatment, the mitochondrial ROS levels in 
response to high glucose challenge in the single pancreatic p-cells of both 
non-diabetic (db^/m^) and diabetic {db+/db+�mice were significantly increased by 
3.8-fold (P < 0.01) and 2.5-fold (P < 0.01) respectively. The combined pre-treatment 
(24-hr) of jasplakinolide (5 |aM) and L-NAC (20 mM) significantly reduced the 
mitochondrial ROS levels in the single pancreatic p-cells of both non-diabetic 
{dbVm") and diabetic (dbVdb^) mice by 57.5 士 1.04o/o (P < 0.01) and 85.5 土 l.Olo/o 
7 6 
{P < 0.01) respectively (Figs. 13 & 14B). 
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Figure 13: Representative live cell confocal microscopic images - mitochondrial 
ROS levels in single pancreatic p-cells of non-diabetic (db+/m+�and diabetic 
�db+ /db+�mice , in response to high glucose (15 mM) challenge, in the absence 
(control) or the presence of L-NAC (20 mM, 24-hr), cytochalasin B (10 juM, 24-hr) 
and jasplakinolide (5 \iM, 24-hr) pre-treatments. Mitochondrial ROS levels were 
estimated using reduced MitoTracker Red (CM-H2XROS) and visualized under 
confocal microscope (60X magnification). The images were taken at the mid-plane 
of cells. Scale bar: 5 jjm or 3 jLon. 
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Figure 14A: Mitochondrial ROS levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic {db^/rn^) and diabetic 
{db^/db^) mice, in response to high glucose (15 mM) challenge, in the absence 
(control) or the presence of L-NAC (20 mM, 24-hr) or cytochalasin B (10 [xM, 24-hr) 
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Figure 14B: Mitochondrial ROS levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabet ic�db+/m+�and diabetic 
{db'^/db^) mice, in response to high glucose (15 mM) challenge, in the absence 
(control) or the presence of L-NAC (20 mM, 24-hr) or jasplakinolide (5 |aM, 24-hr) 
pre-treatment. Data are expressed as means 士 S.E.M. ** P <0.01 (n=3). 
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3.3. Effects of L-NAC, Various Oxidative Stress Inducers/Reducers 
and Actin Polymerisation/Depolymerisation Inducers on F-actin 
Cytoskeleton Levels Incubated in Low Glucose (5 mM) and High 
Glucose (15 mM) Medium in Single Pancreatic P-Cells of 
Non-Diabetic {db'lin) and Diabetic {db'ldb^ Mice 
A significant higher F-actin cytoskeleton level was measured in the control of 
diabetic {db^/db^) mice (10.2-fold; P < 0.01) incubated in low glucose medium and 
(62.6-fold; P < 0.01) in high glucose medium, compared to the corresponding control 
of non-diabetic {db+/m+�mice (Figs. 15 & 16). 
F-actin depolymerisation was apparent in pancreatic cells of diabetic (db^/db^) mice 
after L-NAC (20 mM, 24-hr) pre-treatment. L-NAC significantly reduced the F-actin 
cytoskeleton levels in the pancreatic P-cells of diabetic ( d b V d b � m i c e by 97.7 土 l � / � 
(P < 0.001) incubated in low glucose medium and 93.8 土 P/o (P < 0.001) in high 
glucose medium compared to the corresponding controls (Figs. 15 & 16). 
The oxidative stress inducers (H2O2, thapsigargin and BSO) had similar effects on 
F-actin cytoskeleton levels, which they triggered actin polymerisation only in 
pancreatic p-cells of non-diabetic {db+/m+�mice (Figs. 15A & B), but not in 
pancreatic p-cells of diabetic {db”db+�mice (Figs. 15C & D). 
H2O2 (200 i^M, 24-hr pre-treatment) significantly increased the F-actin cytoskeleton 
8 1 
levels in the pancreatic p-cells of non-diabetic {dbVm+�mice compared to the 
corresponding controls by 13.2-fold (P < 0.001) incubated in low glucose medium 
and 28.0-fold {P < 0.001) at high glucose medium (Figs. 16A & B). In contrast, the 
combined pre-treatment (24-hr) of H2O2 (200 [M) and L-NAC (20 mM) 
significantly reduced the F-actin cytoskeleton levels in pancreatic P-cells of both 
non-diabetic {db+/m+�and iabetic (db^/db^) mice compared to the corresponding 
H2O2 pre-treatment groups (by 57.6 土 1.2o/o, F < 0.01 and 41.5 土 1.76o/o, P < 0.01 
incubated in low glucose medium respectively; by 45.7 ± 1.05%, P < 0.01 and 44.6 土 
2.53%, P < 0 . 0 1 incubated in high glucose medium respectively) (Figs. 16A & B). 
Thapsigargin (0.5 |iM, 24-hr pre-treatment) significantly increased the F-actin 
cytoskeleton levels in pancreatic P-cells of non-diabetic (db”m+�mice compared to 
the corresponding controls by 12.5-fold {P < 0.001) incubated in low glucose 
medium and 55.5-fold (P < 0.01) in high glucose medium respectively. In contrast, 
the combined pre-treatment (24-hr) of thapsigargin (0.5 |LIM) and L-NAC (20 mM) 
significantly reduced the F-actin cytoskeleton levels in pancreatic P-cells of both 
non-diabetic {db^/m^) and diabetic (db^/db^) mice compared to the corresponding 
thapsigargin pre-treatment groups (by 98.3 土 lo/o, P < 0.001 and 11.4 士 1.03o/o, P < 
0.05 incubated in low glucose medium respectively; by 44 土 1.03o/o, P < 0.01 and 
42.3 土 1.390/0, P < 0.001 incubated in high glucose medium respectively) (Figs. 17A 
8 2 
& B ) . 
BSO (0.1 |LIM, 24-hr pre-treatment) significantly increased the F-actin cytoskeleton 
levels in pancreatic p-cells of non-diabetic (db^/m^) mice compared to the 
corresponding controls by 9.9-fold (P < 0.001) incubated in low glucose and 
40.7-fold (P < 0.001) in high glucose medium. In contrast, the combined 
pre-treatment (24-hr) of BSO (0.1 |LIM) and L-NAC (20 mM) significantly reduced 
the F-actin cytoskeleton levels in pancreatic P-cells of both non-diabetic (dbVm+� 
and diabetic (db^/db^) mice compared to the corresponding BSO pre-treatment 
groups (by 50 士 1.12o/o, P < 0.01 and 44.9 土 1.61o/o, P < 0.01 incubated in low 
glucose medium respectively; by 36.8 土 4.1o/o, P < 0.001 and 40.6 土 1.18%, P < 0.01 
in high glucose medium respectively) (Figs. 18A & B). 
On the other hand, oxidative stress reducers (4-PBA and UA) exerted opposite 
effects on F-actin cytoskeleton levels, which they triggered actin depolymerisation in 
pancreatic p-cells of both non-diabetic (db+/m+�and diabetic (db^/db^) mice 
incubated in both low glucose and high glucose medium (Figs. 15A - D). 
4-PBA (1 mM, 24-hr pre-treatment) significantly reduced the F-actin cytoskeleton 
levels in pancreatic p-cells of diabetic (db^/db^) mice compared to the corresponding 
controls by 92.7 土 l � / � ( P < 0.001) incubated in low glucose medium and 97.2 土 lo/o 
{P < 0.01) in high glucose medium (Fig. 19). 
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Similarly, UA (500 |Lig/ml, 24-hr pre-treatment) significantly reduced the F-actin 
cytoskeleton levels in pancreatic p-cells of diabetic {db^/db^) mice compared to the 
corresponding controls by 94.2 土 lo/o (P < 0.001) incubated in low glucose medium 
and 97.6 土 lo/o (P < 0.01) in high glucose medium (Fig. 20). 
Cytochalasin B, an actin depolymerisation inducer, significantly reduced the F-actin 
cytoskeleton levels in pancreatic p-cells of diabetic {db^/db^) mice compared to the 
corresponding controls by 89.2 土 lo/o (P < 0.001) incubated in low glucose medium 
and 98.1 土 IQ/o (P < 0.01) in high glucose medium (Fig. 21). 
In contrast to cytochalasin B, jasplakinolide (actin polymerisation inducer) 
significantly increased the F-actin cytoskeleton levels in pancreatic P-cells of 
non-diabetic {db^/m^) mice compared to the corresponding controls by 14.5-fold (P 
< 0.001) incubated in low glucose medium and 34.5-fold {P < 0.01) in high glucose 
medium. The combined pre-treatment (24-hr) of jasplakinolide (5 |aM) and L-NAC 
(20 mM) significantly reduced the F-actin cytoskeleton levels in pancreatic P-cells 
of both non-diabetic {db^/rn^) and diabetic (db^/db^) mice compared to the 
corresponding jasplakinolide pre-treatment groups (by 54.7 士 3.44o/o, P < 0.01 and 
56.7 土 2.76o/o, P < 0.01 incubated in low glucose medium respectively; by 45.6 士 
1.07%, P < 0.05 and 50.2 士 2.29o/o, P < 0.05 in high glucose medium respectively) 
(Figs. 22A&B). 
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Figure 15A: Representative confocal microscopic images - F-actin cytoskeleton 
levels in single pancreatic P-cells of non-diabetic {dbVm+�mice incubated in low 
glucose (5 mM) medium, in the absence (control) or the presence of (24-hr) L-NAC 
(20 mM), H2O2 (200 ^iM), thapsigargin (0.5 |LIM), jasplakinolide (5 ^iM), BSO (0.1 
|aM), cytochalasin B (10 j^M), 4-PBA (1 mM) or UA (500 |ag/ml) pre-treatments and 
the combined pre-treatments (as indicated). The actin cytoskeletons were visualized 
under confocal microscope (60X magnification) and the intensities were measured 
using fluorescently labelled phalloidin (shown as green colour). Nuclear staining 
with Hoechst 33342 (shown as blue colour) was used to observe morphological 
changes. The images were taken at the mid-plane of cells. Scale bar: 5/jm. 
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Figure 15B: Representative confocal images - F-actin cytoskeleton levels in single 
pancreatic p-cells of non-diabetic (db^/m^) mice incubated in high glucose (15 mM) 
medium, in the absence (control) or the presence of (24-hr) L-NAC (20 mM), H2O2 
(200 i^M), thapsigargin (0.5 \iM), jasplakinolide (5 laM), BSO (0.1 |LIM), 
cytochalasin B (10 |LIM), 4-PBA (1 mM) or UA (500 |Lig/ml) pre-treatments and the 
combined pre-treatments (as indicated). The actin cytoskeletons were visualized 
under confocal microscope (60X magnification) and the intensities were measured 
using fluorescently labelled phalloidin (shown as green colour). Nuclear staining 
with Hoechst 33342 (shown as blue colour) was used to observe morphological 
changes. The images were taken at the mid-plane of cells. Scale bar: 5jum. 
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Figure 15C: Representative confocal images - F-actin cytoskeleton levels in single 
pancreatic P-cells of diabetic {db^/db^) mice incubated in low glucose (5 mM) 
medium, in the absence (control) or the presence of (24-hr) L-NAC (20 mM), H2O2 
(200 i^M), thapsigargin (0.5 ^iM), jasplakinolide (5 |aM), BSO (0.1 ^iM), 
cytochalasin B (10 ^iM), 4-PBA (1 mM) or UA (500 |Lig/ml) pre-treatments and the 
combined pre-treatments (as indicated). The actin cytoskeletons were visualized 
under confocal microscope (60X magnification) and the intensities were measured 
using fluorescently labelled phalloidin (shown as green colour). Nuclear staining 
with Hoechst 33342 (shown as blue colour) was used to observe morphological 
changes. The images were taken at the mid-plane of cells. Scale bar: 5/Mn. 
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Figure 15D: Representative confocal images - F-actin cytoskeleton levels in single 
pancreatic P-cells of diabetic {db^/db^) mice incubated in high glucose (15 mM) 
medium, in the absence (control) or the presence of (24-hr) L-NAC (20 mM), H2O2 
(200 nM), thapsigargin (0.5 |aM), jasplakinolide (5 ^iM), BSO (0.1 |LIM), 
cytochalasin B (10 |LIM), 4-PBA (1 mM) or UA (500 jig/ml) pre-treatments and the 
combined pre-treatments (as indicated). The actin cytoskeletons were visualized 
under confocal microscope (60X magnification) and the intensities were measured 
using fluorescently labelled phalloidin (shown as green colour). Nuclear staining 
with Hoechst 33342 (shown as blue colour) was used to observe morphological 
changes. The images were taken at the mid-plane of cclls. Scale bar: 5jiini. 
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Figure 16A: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic (db+/m+�and diabetic 
{db''/db^) mice incubated in low glucose (5 mM) medium, in the absence (control) or 
the presence of 24-hr L - N A C (20 mM) or H2O2 (200 |LIM) pre-treatment. Data are 
expressed as means 士 S.E.M. **P<0.01 and *** P < 0.001 (n=3). 
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Figure 16B: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic (db+/m+�and diabetic 
{db”db+�mice incubated in high glucose (15 mM) medium, in the absence (control) 
or the presence of 24-hr L-NAC (20 mM) or H2O2 (200 |iM) pre-treatment. Data are 
expressed as means 土 S.E.M. ** P <0.01 and *** P < 0.001 (n二3). 
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Figure 17A: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic (db+/m+�and diabetic 
(db^'/db^) mice incubated in low glucose (5 mM) medium, in the absence (control) or 
the presence of 24-hr L-NAC (20 mM) or thapsigargin (0.5 |LIM) pre-treatment. Data 
are expressed as means 士 S.E.M. * P < 0.05, ** P <0.01 and *** P < 0.001 (n二3). 
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Figure 17B: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic {db^/m^) and diabetic 
(db^/db^) mice incubated in high glucose (15 mM) medium, in the absence (control) 
or the presence of 24-hr L-NAC (20 mM) or thapsigargin (0.5 ^iM) pre-treatment. 
Data are expressed as means 士 S.E.M. ** P <0.01 and *** P < 0.001 (n=3). 
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Figure 18A: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic {dh^/m^) and diabetic 
{dbVdb"^�mice incubated in low glucose (5 mM) medium, in the absence (control) or 
the presence of L-NAC (20 mM, 24-hr) or BSO (0.1 |LIM, 24-hr) pre-treatment. Data 
are expressed as means ± S.E.M. ** P <0.01 and *** P < 0.001 (n=3). 
93 
High glucose (15 mM) 
_ 1500000.0-1 _ 
> I i i i , , m_, 口（db+/m+) mice 




o 2 _ 
S^S 500000.0- _ 
0.0 
、乂。\、、。\ / / J" / 拿 
。。•银々,y 
V V V V 
A/ 
Figure 18B: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic (db+/m+�and diabetic 
{db+/db+�mice incubated in high glucose (15 mM) medium, in the absence (control) 
or the presence of L-NAC (20 mM, 24-hr) or BSO (0.1 |aM, 24-hr) pre-treatment. 
Data are expressed as means 士 S.E.M. ** P <0.01 and *** P < 0.001 (n=3). 
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Figure 19: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic {db”m+�and diabetic 
{db^/db^) mice incubated in low glucose (5 mM) and high glucose (15 mM) medium, 
in the absence (control) or the presence of L-NAC (20 mM, 24-hr) or 4-PBA (1 mM, 
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Figure 20: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic {dbVm+~) and diabetic 
(db^/db^) mice incubated in low glucose (5 mM) and high glucose (15 mM) medium, 
in the absence (control) or the presence of L-NAC (20 mM, 24-hr) or UA (500 ^ig/ml, 
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Figure 21: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic ( d b ” m + � a n d diabetic 
(db^/db^) mice incubated in low glucose (5 mM) and high glucose (15 mM) medium, 
in the absence (control) or the presence of L-NAC (20 mM, 24-hr) or cytochalasin B 
(10 jJM, 24-hr) pre-treatment. Data are expressed as means 土 S.E.M. ** F <0.01 and 
*** P < 0.001 (n=3). 
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Figure 22A: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic p-cells of non-diabetic (dbVm+�and diabetic 
{db”db+�mice incubated in low glucose (5 mM) medium, in the absence (control) or 
the presence of L-NAC (20 mM, 24-hr) or jasplakinolide (5 |iM, 24-hr) pre-treatment. 
Data are expressed as means 士 S.E.M. ** P <0.01 and *** P < 0.001 (n=3). 
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Figure 22B: F-actin cytoskeleton levels (expressed as AUC (area under curve) in 
arbitrary units) in single pancreatic P-cells of non-diabetic {dbVm+�and diabetic 
{dbVdb七、mice incubated in high glucose (15 mM) medium, in the absence (control) 
or the presence of L-NAC (20 mM, 24-hr) or jasplakinolide (5 ^iM, 24-hr) 




4.1. General Discussion 
Type 2 diabetes mellitus (T2DM) is a heterogeneous, complex and common disease, 
affecting about 100 million people worldwide (approximate 90-95% of all cases 
diagnosed) (Rolo et al., 2006; Sivitz et al., 2010). T2DM associates with progressive 
deterioration of pancreatic islets P-cells functions and insulin resistance, resulting in 
insufficient insulin secretion and synthesis in response to glucose (Fonseca et al., 
2009; Rolo et al.,2m6). 
The inbred mouse strain (C57BL/KsJ) non-diabetic/lean {db^/m") and genetically 
diabetic {db”db+�mice were used as the animal models for T2DM in this study. 
Genetically, diabetic (db^/db'') mice are lack of leptin receptor and demonstrated 
severe leptin resistance (Ikeda et al., 2011). Diabetic {db”db+�mice are 
hyperglycemic, spontaneously hyperphagic, hyperinsulinemic and insulin resistant 
associated with progressive deterioration of pancreatic islets P-cells functions / 
activities (Coleman, 1978; Hummel et al., 1966). Therefore, diabetic {db+/db+�mice 
are widely used as a rodent model of human T2DM research. Effects of drugs in 
non-diabetic/lean mice were also investigated for comparison. Uchiyama et 
al (2002) reported that the fasting glucose level measured in blood of diabetic 
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{db'^/db^) mice is � 1 5 mM. Therefore, 15 mM glucose was used to mimic / simulate 
the pathophysiological conditions of hyperglycemia as observed in diabetic {dbVdb+� 
mice. 
It has been well documented that high blood glucose (i.e. hyperglycemia) elicits the 
production of harmful free radicals which induces oxidative stress through both 
enzymatic and non-enzymatic reactions (Codario. 2011). Under the state of 
hyperglycaemia, the transmembrane proton gradient (ApH) and hyperpolarisation of 
the membrane potential (A平m) inhibit the proton pumps to generate high 
electrochemical potential difference, and the ATP/ADP ratio is thus increased (Rolo 
et al., 2006). Glucose oxidation causes the formation of toxic hydroxy radicals within 
the mitochondria. The highly reactive hydroxy radicals are readily converted to 
hydrogen peroxide (H2O2) which can damage the cells directly via oxidation in 
mitochondrial DNA, lipids, proteins and cellular structures including Ca�— ions 
regulatory organelles (Narayan et al., 2003). The increase of intracellular Ca^^ can 
turn on the vicious cycle which stimulates the further generation of mitochondrial 
ROS (Newsholme et al., 2007; Rolo et aL, 2006). The elevated ROS levels reduces 
insulin gene transcription and induces apoptosis of pancreatic islets p-cells (Tajiri et 
al., 1997). Unfortunately, pancreatic islets have the lowest intrinsic antioxidant 
capacity compared with other tissues and contain relatively low activities of major 
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antioxidant enzymes (Cu/Zn SOD, Mn SOD and GPx) (Robertson et al., 2004). This 
explains why the pancreatic islets P-cells are vulnerable to oxidative damage and the 
obvious primary target of oxidative stress under hyperglycemia. In fact, there are 
convincing evidence that oxidative stress under hyperglycaemic conditions 
contributes significantly to T2DM development due to the impaired insulin 
secretion/synthesis (because of pancreatic islets P-cell dysfunction) and reduction of 
the mass of pancreatic islets p-cells (Baynes et al., 1999; Giugliano et al., 1996; 
Goldstein, 2002; Haber et al., 2003; Kaneto et al., 1999; Paolisso et al., 1994; 
Paolisso et al, 1996; Robertson et al, 2004). 
Although the association of oxidative stress and hyperglycemia has been already 
studied for many years, there is still very little convincing evidence, and the detailed 
cellular mechanisms involved, of the uses of anti-oxidants in treating the dysfunction 
of pancreatic islets P-cells as observed in T2DM. Therefore, this study was designed 
to evaluate the beneficial effects of L-NAC (a common anti-oxidant) in the 
pancreatic islets P-cells of non-diabetic/lean {db+/m+�and obese/diabetic (db+/db+� 
mice bathed in normal / low glucose (5 mM) and high glucose (15 mM) culture 
medium. It has been reported that L-NAC works effectively in different cells / 
systems between 3.5 [xU to 43 mM (de Toledo Fomazari et al., 2005). Furthermore, 
L-NAC is water soluble and it enters the cells readily only when using a relatively 
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high concentration (Meredith et al., 1995; Packer et al., 1995). Therefore, 20 mM of 
L-NAC was employed in this in vitro study. 
Figure 11 illustrates that the basal mitochondrial ROS level was higher in the single 
pancreatic islets p-cells of diabetic (db^/db^) mice bathed in normal (5 mM) glucose 
medium (control) (time = 0), compared to the single pancreatic islets P-cells of 
non-diabetic/lean (db^/m^) mice bathed in normal (5 mM) glucose medium (control). 
Our results clearly demonstrate that there was lower amount of insulin release from 
isolated pancreatic islets of obese/diabetic (db^/db^) mice, compared to the isolated 
pancreatic islets of lean/non-diabetic {db^/m^) mice, in response to high glucose (15 
mM) challenge. Moreover, the insulin content (non-releasable insulin) of isolated 
pancreatic islets of obese/diabetic {db^/db^) mice was lower compared to the isolated 
pancreatic islets of lean/non-diabetic {db^/m") mice. Interestingly, L-NAC treatment 
(20 mM, 24 hr) successfully restored the blunted glucose-induced insulin release and 
the insulin content of isolated pancreatic islets of obese/diabetic {dbVdb+�mice. 
Using confocal microscopy, our results clearly demonstrate that an excessive ROS 
generation occurred in the pancreatic islets P-cells of diabetic {db'^/db^) mice even 
under normal glucose level (5 mM), compared to the pancreatic islets P-cells of lean 
(db+/m+) mice, and the mitochondrial ROS level continued to increase in response to 
high glucose (15 mM) challenge. In contrast, the mitochondrial ROS level was 
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relatively low, compared to the isolated pancreatic islets p-cells of obese/diabetic 
(db^/db^) mice, in the isolated pancreatic P-cells of non-diabetic/lean (db+/m+�mice 
irrespective of the glucose levels in the culture medium. These results suggest that 
the isolated pancreatic islets p-cells of non-diabetic/lean (db+/m+�mice are capable 
of scavenging the mitochondrial ROS production more effectively / efficiently in 
response to glucose challenges, compared to the isolated pancreatic islets p-cells of 
obese/diabetic (db^/db^) mice, probably by the higher levels of antioxidant 
enzymatic activities available. However, the mitochondrial ROS level increased in 
response to high glucose (15 mM) stimulation suggesting that the excessive ROS 
production cannot be effectively diminished by the antioxidant enzyme activities in 
the pancreatic islets P-cells of non-diabetic/lean {db^/m^) mice and this contributes, 
to a certain extent, oxidative stress (due to the generation of excessive mitochondrial 
ROS which could not be eliminated by the available cellular anti-oxidants) even in 
pancreatic islets p-cells of lean / normal {db+/m+�mice. 
To investigate the antioxidant effects of L-NAC on mitochondrial ROS generation, 
isolated pancreatic islets P-cells were pre-treated with L-NAC (20 mM, 24 hr). 
L-NAC pre-treatment was capable of reducing the mitochondrial ROS levels 
measured in the isolated pancreatic islets P-cells of both non-diabetic (db+/m+�and 
diabetic {db”db+�mice bathed in normal (5 mM) glucose medium, compared to the 
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corresponding controls. Thus, our results clearly demonstrated that L-NAC can 
ameliorate oxidative stress in the pancreatic islets P-cells by reducing mitochondrial 
ROS production. It is important to point out that L-NAC pre-treatment significantly 
suppressed the mitochondrial ROS generation ( � 4 0 % reduction) in the single 
pancreatic islets p-cells of diabetic {db”clb+�mice in response to high glucose (15 
mm) challenge, whereas L-NAC did not cause a significant change in the 
mitochondrial ROS levels in the single pancreatic islets p-cells of non-diabetic/lean 
�db"/m—�mice (Fig. 11 & 12). These results demonstrated that L-NAC pre-treatment 
can effectively prevent the excessive ROS production in the single pancreatic islets 
P-cells of diabetic {db^/db^) mice (in which the cellular anti-oxidant capacity is very 
low) in response to high glucose stimulation. Our results are consistent with previous 
study in isolated rat pancreatic islets (Robertson et al., 2004) in which the 
intracellular peroxide level increased by high glucose (11.1 mM) and ribose was 
greatly diminished by NAC. Moreover, a marked decrease of ROS levels has been 
observed 48-hr after L-NAC treatment in mice isolated pancreatic islets cultured in 
high glucose (16.7 mM) medium (Zraika et aL, 2009). Taken together, results of the 
present study and from others provide convincing evidences that L-NAC is effective 
in reducing the mitochondrial ROS production in the pancreatic p-cells of diabetic 
{db^/db^) mice under hyperglycaemic conditions. 
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Thapsigargin is a commonly used oxidative stress inducer which caused pancreatic 
3-cell loss and increases the rate of apoptosis through impairing cell cycle 
progression in clonal (3-cell line MIN6 cells (Harding et al, 2002; Riggs et al., 2005; 
Wu et al, 2006; Yamada et al., 2006). Therefore, in this study, thapsigargin was used 
to mimic the pathophysiological oxidative stress conditions (in response to 
hyperglycemia) in the pancreatic P-cells of non-diabetic (db'^/m^) and diabetic 
( d b V d b � m i c e . After the isolated pancreatic islets p-cells of non-diabetic (db^/m^) 
and diabetic {db^/db^) mice were incubated with thapsigargin (0.5 ^iM, 24-hr) in 
normal glucose (5 mM) and high glucose (15 mM) medium (at time = 0 min) (Fig. 
11), a significant higher mitochondrial ROS levels was detected. In the isolated 
pancreatic islets P-cells of non-diabetic (db^/m^) mice, a lower level of 
glucose-induced insulin release plus insulin content were detected, compared to the 
respective controls. Our results demonstrate that thapsigargin enhanced 
mitochondrial ROS generation in the isolated pancreatic islets P-cells of both 
non-diabetic and diabetic {db"7db+�mice in response to high glucose 
stimulation which can contribute to oxidative stress and the associated attenuation of 
pancreatic islets p-cell functions such as glucose-induced insulin secretion and 
insulin content (Fig. 11 & 12D), as observed in T2DM. 
In addition, when the pancreatic P-cells of both non-diabetic/lean and 
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obese/diabetic {db^/db^) mice were incubated with H2O2 (a ROS) in normal glucose 
(5 mM) medium (Fig. 11), a higher level of ROS was only detected in the single 
pancreatic islets p-cells of diabetic {db^/db^) mice but not in the single pancreatic 
islets p-cells of non-diabetic/lean {dbVm+�mice. However, H2O2 enhanced the 
mitochondrial ROS levels in the single pancreatic islets P-cells of both 
non-diabetic/lean (db^/m^) and obese/diabetic {db"7db+�mice in response to high 
glucose (15 mM) stimulation (Fig. 11 & 12C). These results therefore strongly 
suggest that the pancreatic islets P-cells of non-diabetic/lean (db+/m+) mice are 
capable of scavenging, only to a certain extent when there is not a very high level of 
ROS formed probably via the available antioxidant enzymes. It has demonstrated 
(Robertson et al., 2004) that fewer antioxidant enzyme expressions were detected in 
the pancreatic islets p-cells of diabetic {dh^/db^) mice for converting H2O2 (and 
probably other ROS as well) to other non-toxic substances. Perhaps, it can explain 
why there is always a higher mitochondrial ROS levels measured in the single 
pancreatic islets p-cells of diabetic (db^/db^) mice under basal conditions and in 
response to glucose challenge compared to the isolated pancreatic islets of 
lean/non-diabetic (db^/m^) mice. However, the level and the identity of antioxidant 
enzymes present in the pancreatic islets lean/non-diabetic ( d b ” m + � a n d diabetic 
(db^/db^) mice have not been measured and compared in this study. 
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So far, we have demonstrated that thapsigargin and H2O2 are capable of enhancing 
the excessive ROS generation in the single pancreatic islets p-cells of both 
non-diabetic (db^/m^) and diabetic (db^/db^) mice, leading to oxidative stress under 
normal (5 mM) glucose and high (15 mM) glucose stimulation (Fig. 11, 12C and 
12D). Interestingly, L-NAC pre-treatment (20 mM, 24 hr) was capable of preventing 
the single pancreatic islets p-cells of both non-diabetic (db^/m^) and diabetic 
(db^/db^) mice from oxidative stress insults by reducing the mitochondrial ROS 
generation (Fig. 11, 12C and 12D). In fact, our result is consistent with a previous 
report in which an excessive ROS generation induced by H2O2 in rat insulinoma cells 
(RINm cells) and mouse insulin-producing pancreatic P-cells (MIN6) was abrogated 
by L-NAC treatment (Sampson et al., 2010). 
To strengthen our conclusion on the involvement of oxidative stress, 
DL-Buthionine-[S,R]-Sulfoximine (BSO) was used in this study. BSO is an oxidative 
stress inducer and an irreversible inhibitor of y-glutamylcysteine synthetase (y-GCS) 
(an important enzyme involved in cellular glutathione synthesis) (Fig. 1) (Griffith et 
al., 1999; Mizuno et al., 2011). After BSO treatment (24 hr), there was a reduction in 
glucose-induced insulin release and insulin content of isolated pancreatic islets 
p-cells of lean/non-diabetic (db^/m^) mice whereas there was no apparent change in 
obese/diabetic {db+/db+�mice. Similar to thapsigargin, BSO pre-treatment resulted in 
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a significantly higher mitochondrial ROS level measured in single pancreatic islets 
P-cells of lean/non-diabetic (db^/m^) and obese/diabet ic�db”db+�mice bathed in 
normal glucose (5 mM) medium (at time = 0) (Fig. 11). Under high glucose (15 mM) 
conditions, even higher levels of mitochondrial ROS were detected, after BSO 
treatment, in the pancreatic P-cells of both non-diabetic {db”m+�and diabetic 
{db^/db^) mice in response to high glucose (15 mM) stimulation (Fig. 11, 12E). The 
presence of L-NAC (20 mM, 24 hr) during the pre-treatment with BSO (0.1 ^M, 
24-hr) markedly suppressed the effects (i.e. an increased mitochondrial ROS level) of 
BSO in single pancreatic islets P-cells of l e an /non -d i abe t i c�db”m+�and 
obese/diabetic (db^/db^) mice bathed under basal glucose (5 mM) level and in 
response to high glucose (15 mM) challenge (Fig. 11, 12E). Therefore, our results 
suggest that BSO attenuated glucose-induced insulin release and insulin content of 
isolated pancreatic islets p-cells which are probably via the generation of 
mitochondrial ROS, and the ROS generated can be neutralized by L-NAC. 
It has been well documented that glutathione synthesis plays a critical role in the 
protective effects of L-NAC treatment in the pancreatic islets p-cells under 
hyperglycemia. Glutathione (GSH) is a natural antioxidant in mammalian cells for 
cellular defence against ROS (Wu et al., 2004). BSO is an inhibitor of GSH synthesis 
and thus it prevents the effective removal of ROS generated in the pancreatic islets 
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p-cells, and therefore it is anticipated that more ROS are accumulated within the 
cells. BSO (0.1 fiM) significantly suppressed the intracellular GSH content and the 
combined pre-treatment with L-NAC partially restored the intracellular GSH levels 
in cultured rat striatal muscles (Guarino et al., 2006; Mizuno et al, 2011). Although, 
in out study, we did not measure intracellular GSH levels in pancreatic islets p-cells 
of both strains of mice (before and after drug treatments), it is reasonable to suggest 
that L-NAC treatment is capable of promoting ROS removal / clearance by 
supplying an extra amount of intracellular GSH in order to reduce the oxidative 
stress damage inside the cells. 
In addition to thapsigargin and BSO (both are oxidative stress inducers), we have 
examined the effects of oxidative stress reducers: 4-phenyl butyric acid (4-PBA) and 
ursodeoxycholic acid (UA) and determined whether these drugs can mimic the 
beneficial effects of L-NAC. They are chemical chaperones which can abolish 
oxidative damage within the cells. Consistent with our results on L-NAC treatments 
as mentioned above, the mitochondrial ROS levels in the pancreatic P-cells of both 
non-diabetic (db+/m+) and diabetic (db^/db^) mice under the basal glucose conditions 
were lower, compared to the respective controls, after pre-treated with 4-PBA and 
UA (Fig. 11). 4-PBA enhanced both glucose-induced insulin secretion and insulin 
content/synthesis in single pancreatic islets P-cells of diabetic {dbVdb+�mice (Fig. 5). 
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However, UA only improved the insulin content/synthesis but not glucose-induced 
insulin secretion, in pancreatic p-cells of diabetic (db^/db^) mice (Fig. 6). In fact, UA 
mainly improved hepatic ER stress and insulin sensitivity for the regulation of 
hepatic gluconeogenesis and glycogen synthesis in liver (Trauner et al., 2010). Thus, 
it may not have similar beneficial effects as 4-PBA and L-NAC on glucose-induced 
insulin secretion from the readily releasable pool in pancreatic islets p-cells. It has 
been reported that UA caused F-actin cytoskeleton reorganisation, which leaded to 
stimulation of insulin-induced gene expression (Tsakiridis et al., 1999). It is therefore 
anticipated that more insulin granules were produced and stored within the pancreatic 
islets P-cells (i.e. insulin content) for the subsequent release upon the challenge with 
glucose. 
In addition, 4-PBA and UA treatments, similar to L-NAC pre-treatments, 
significantly suppressed the mitochondrial ROS generation in single pancreatic islets 
P-cells of diabetic (db^/db^) mice in response to high glucose challenge, but not in 
the single pancreatic islets P-cells of lean/non-diabetic (db+/m+�mice (Fig. 12A & 
12B). In fact, it has been shown (Ozcan et al., 2006) that 4-PBA or UA pre-treatment 
in obese mice caused a reduction of oxidative stress markers (p-PERK and JNK), 
reduced blood glucose levels back to normoglycemic conditions by increasing 
systemic insulin sensitivity. They can also improve the endoplasmic reticulum (ER) 
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folding capacity in order to protect the pancreatic p-cells against oxidative stress and 
reverse insulin resistance in T2DM (Ozcan et al., 2006; Xie et al., 2002). Taken 
together, our results implicate that L-NAC pre-treatments is effective for preventing 
pancreatic islets p-cells damage by attenuating oxidative stress responses. 
It has been documented that a dense cortical actin network is located beneath cell 
membrane of pancreatic islets p-cells which acts as a barrier for insulin granule 
docking and fusion to cell membrane (i.e. inhibition of insulin vesicles exocytosis). 
This cortical actin network is the vulnerable primary target of oxidative stress which 
contributes to cellular aging and apoptosis (Farah et al., 2007). The redox state of 
actin causes reduction of actin dynamics which enhances cellular ROS accumulation 
(Gourlay et al., 2004). Cell survival is also regulated by actin dynamics and F-actin 
cytoskeleton hyperstabilisation causes apoptosis and cell death in mammalian cells 
(Farah et al., 2007; Gourlay et al., 2004; Rao et al., 1999). In fact, F-actin 
cytoskeleton is highly dynamic which can be readily reorganised in response to many 
growth factors and intrinsic signals (Ridley, 1999). 
Glucose-induced insulin secretion is biphasic in normal subjects. The first phase is 
rapid with a sharp peak, which lasts for less than 10 minutes. The second phase is 
constant, prolonged plateau which lasts for the whole elevated blood glucose period 
(Fonseca et al., 2009). The first phase corresponds to insulin release from a cluster of 
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secretory vesicles which are already docked at the cell membrane and waiting for 
F-actin cytoskeleton depolymerisation. The second phase represents the recruitment 
of insulin-containing secretory vesicles from cell interior and a prolonged F-actin 
disruptions contributes to immediate release of insulin (Hummel et al, 1966). It has 
been reported that failure of insulin secretion is closely associated with F-actin 
cytoskeleton polymerisation (Tomas et al., 2006; Wang et al, 2009). Glucose 
stimulation triggers transient F-actin remodelling to allow insulin-containing 
granules access to plasma membrane for subsequent docking, fusion and release 
(Wang et al, 2009). 
It has been documented in endothelial cells that L-NAC can reduce the free radicals 
production and the total amount of F-actin cytoskeleton (Moldovan et al., 1999). 
Moreover, Farah et al. (2007) reported that L-NAC not only suppressed the F-actin 
polymerisation, but also reduced the accumulated excessive ROS and abrogated the 
intracellular oxidative stress in yeast cells. In our study, a significantly higher level of 
F-actin cytoskeleton was detected in the single pancreatic islets P-cells (control) of 
diabetic {db^/db^) mice bathed in low glucose (5 mM) and high glucose (15 mM) 
medium, compared to the single pancreatic islets P-cells of non-diabetic (dbVm+� 
mice (Fig. 16A & B). For the same strain of mice, an increase in glucose levels in the 
medium (i.e. from 5 to 15 mM) (24 hr incubation) resulted in an increase in F-actin 
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cytoskeleton levels (Fig. 15D) suggesting that glucose levels has profound effects on 
F-actin cytoskeleton which can alter insulin release/synthesis. 
L-NAC (20 mM, 24-hr pre-treatment) significantly facilitated F-actin 
depolymerisation / reduction of F-actin cytoskeleton levels in the pancreatic p-cells 
of both non-diabetic {db^/m^) and diabetic (db^/db^) mice bathed in normal glucose 
(5 mM) and high glucose (15 mM) medium, compared to the corresponding controls 
(Fig. 15 & 16). As mentioned above, L-NAC (20 mM, 24-hr pre-treatment) 
successfully restored the blunted glucose-induced insulin secretion and insulin 
contents in single pancreatic islets of obese/diabetic {db^/db'') mice (Fig. 4A & 4B). 
Taken together, our results suggest that L-NAC is effective in promoting F-actin 
depolymerisation / reduction of F-actin cytoskeleton levels (which facilitates the 
movement of insulin-containing granules from the releasable pool to fuse with cell 
membrane for insulin secretion) in isolated pancreatic islets P-cells of obese/diabetic 
{dbVdh^�mice via its antioxidant activities on suppressing the mitochondrial ROS 
generation (probably by enhancing intracellular GSH levels). 
To further confirm our findings on the roles of F-actin cytoskeleton, cytochalasin B 
(10 |iM, an actin depolymerising drug) and jasplakinolide (5 an actin 
polymerising drug) were examined. Mourad et al, (2010) demonstrated that 
cytochalasin B disrupted the cortical F-actin network in rat pancreatic islets P-cells 
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and decreased F-actin cytoskeleton levels. F-actin cytoskeleton disruption by 
cytochalasin B increased the number of insulin-containing granules from releasable 
pools and promoting the docking and fusion underneath cell membrane (Jewell et al., 
2008; Van Obberghen et aL, 1975). In addition, Cytochalasin B augments two phases 
of glucose-induced insulin secretion. In general, F-actin cytoskeleton is unable to be 
depolymerised in pancreatic P-cells of diabetic {db”db+�mice in response to glucose 
(5 and 15 mM) challenges (Fig. 15C & D and 16). Cytochalasin B (10 ^iM, 24-hr 
pre-treatment) caused F-actin depolymerisation / reduction of F-actin cytoskeleton 
levels in single pancreatic islets p-cells of obese/diabetic (db^/db^) mice bathed in 
normal glucose (5 mM) and high glucose (15 mM) medium (Fig. 15C & D, 21). 
However, it has no apparent effects on F-actin depolymerisation / reduction of 
F-actin cytoskeleton levels in single pancreatic islets p-cells of lean/non-diabetic 
{db^/m'') mice (Fig. 15A & B, 21). Similar to L-NAC, Cytochalasin B pre-treatments 
resulted in an attenuation of mitochondrial ROS levels (in response to glucose 
challenges) as well as the restoration of the attenuated glucose-induced insulin 
release and insulin content of single pancreatic islets P-cells of obese/diabetic 
(db^/db^) mice. 
It has been clearly demonstrated that jasplakinolide enhanced F-actin polymerisation 
in MIN6 insulin-secreting cells, and caused a reduction of glucose-induced insulin 
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secretion (Mourad et al., 2010; Nevins et al., 2003). In our study, jasplakinolide (5 
I^M, 24-hr pre-treatment) polymerised F-actin cytoskeleton / increased F-actin 
cytoskeleton levels in single pancreatic islets p-cells of lean/non-diabetic (db^/m^) 
mice bathed in normal glucose (5 mM) medium whereas no apparent change was 
observed in single pancreatic islets P-cells of lean/non-diabetic {db^/m^) mice bathed 
in high glucose (15 mM) medium (Fig. 15A & B, 22A & B). In contrast, 
jasplakinolide polymerised F-actin cytoskeleton / increased F-actin cytoskeleton 
levels in single pancreatic islets P-cells of obese/diabetic (db^/db^) mice bathed in 
both normal (5 mM) glucose and high glucose (15 mM) medium (Fig. 15C & D, 22A 
& B). In addition, similar to other oxidative stress inducers studied as mentioned 
above, jasplakinolide treatments resulted in an increase in mitochondrial ROS 
generation of single pancreatic islets p-cells of both strains of mice in response to 
glucose challenges. In fact, H2O2 enhanced mitochondrial ROS levels and promoted 
actin polymerisation and formation of stress fibers (actin-myosin filaments) (San 
Martin et al., 2010). Nonetheless, our results suggest that, for the first time, the 
isolated pancreatic islets p-cells of lean/non-diabetic {dbVm�mice are capable to be 
depolymerised (F-actin cytoskeleton) spontaneously in response to high glucose 
stimulation for the "ultimate" consequences (i.e. insulin granules docking, fusion and 
release). Perhaps, these results can explain the redundancy of the functions of 
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pancreatic islets of obese/diabetic (dbVdb+�mice in response to glucose challenge 
and the subsequent insulin release because of the failure in the depolymerisation of 
F-actin cytoskeleton under hyperglycaemic conditions. This hypothesis is supported 
by the fact that, in our study, Cytochalasin B significantly enhanced the 
glucose-induced insulin secretion and insulin contents in isolated pancreatic islets of 
diabetic�db+/db+�mice bathed in low glucose (5 mM) and high glucose (15 mM) 
medium, whereas it only enhanced glucose-induced insulin secretion and insulin 
contents in isolated pancreatic islets of non-diabetic (db^/m^) mice in response to 
low glucose stimulation (Fig. 4). Moreover, jasplakinolide reduced the 
glucose-induced insulin secretion and insulin contents in isolated pancreatic islets of 
obese/diabetic (dbVm+�mice bathed in low glucose (5 mM) and high glucose (15 
mM) medium. The presence of L-NAC during the treatment with jasplakinolide (24 
hr) effectively restored the suppressed (as caused by jasplakinolide alone) 
glucose-induced insulin secretion and insulin contents in single pancreatic islets of 
both non-diabetic (db”m+�and iabetic {db^/dh^) mice bathed in low glucose (5 mM) 
and high glucose (15 mM) medium (Fig. 8). Hence, our results demonstrate that, 
similar to L-NAC, cytochalasin B restored the blunted glucose-induced insulin 
secretion/insulin content of isolated pancreatic islets of obese/diabetic {db^/dh^) mice 
by facilitating F-actin depolymerisation and suppressing mitochondrial ROS 
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generation. The successful abrogation of jasplakinolide by L-NAC further strengthen 
the obligatory roles of F-actin cytoskeleton polymerisation (Fig. 13, 14A & B, 22A & 
B) and mitochondrial ROS generation in mediating the redundancy of insulin release 
in response to glucose stimulation as commonly observed in T2DM. 
Huot et al., (1997) demonstrated that H2O2 caused F-actin fragmentation in 
fibroblasts and induced F-actin remodelling in endothelial cells, which further lead to 
accumulation of stress fibers. The combined pre-treatment of these oxidative stress 
inducers and L-NAC, L-NAC significantly reversed the effects of these oxidative 
stress inducers in the pancreatic islets/p-cells of both non-diabetic {db^/rn^) and 
diabetic (db^/db^) mice, which restored the insulin secretion and synthesis by 
attenuated oxidative damage within the cells. Cross-links between F-actin filaments 
are produced by the intramolecular disulfide-boned actin filaments for F-actin 
polymerisation during ROS-induced G-actin oxidation, and thus, this causes increase 
in the elasticity of F-actin network (San Martin et al., 2010). L-NAC is capable to 
break the disulfide bonds and disrupt ionic binding of calcium of mucoproteins 
through its free sulfhydryl group (Packer et al., 1995). Therefore, L-NAC can break 
the disulfide bonds between the actin filaments for F-actin polymerisation, leading to 
F-actin depolymerisation for promoting the insulin granule exocytosis. 
And, for the first time, the results showed that 4-PBA and UA reduced F-actin 
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cytoskeleton level in pancreatic p-cells of diabetic {db”db+�mice in response to both 
low glucose and high glucose stimulations, whereas they did not have effects in 
pancreatic (3-cells of non-diabetic (db+/m+�mice (Fig. 15C & D, 19 and 20). 
In conclusion, our results clearly illustrate that, for the first time, L-NAC (a common 
anti-oxidant) pre-treatment offers an effective protection / beneficial effects to 
isolated pancreatic islets of obese/diabetic {db^/db^) mice in response to elevated 
glucose challenge (i.e. hyperglycaemic conditions) via inhibition of mitochondrial 
ROS generation (probably by increasing intracellular GSH levels) and promotion of 
depolymerisation of F-actin cytoskeleton. These beneficial effects, combined 
together, facilitate glucose-induced insulin secretion and /or insulin synthesis as well 
as the restoration of pancreatic islets P-cell dysfunction (due to an elevated basal 
oxidative stress and F-actin cytoskeleton polymerization) can offer some hope in 
using L-NAC clinically in treating T2DM in the future. 
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6. FUTURE PERSPECTIVES 
This in vitro study illustrates that L-NAC (a common anti-oxidant) is effective in 
improving the impaired glucose-induced insulin secretion by reducing oxidative 
stress / damage (via scavenging mitochondrial ROS generated), and F-actin 
cytoskeleton level in response to elevated glucose in pancreatic p-cells of 
obese/diabetic (dbVdb+�mice. 
The dynamic control of F-actin cytoskeleton and small GTPase proteins (such as 
cdc42, RhoA, Racl and the Ras-like family) have been suggested to be involved in 
the events of glucose-induced insulin secretion/synthesis under oxidative stress and 
hyperglycemia. Moreover, the secretory proteins (i.e. SNARE proteins) and small 
GTPase proteins have been identified in pancreatic islets, but their essential roles and 
their actions in glucose-induced insulin secretion and insulin synthesis especially 
under hyperglycemic conditions, with and without L-NAC treatments, remains to be 
established. 
On the other hand, it is well known that hyperglycemia leads to glucotoxicity, which 
contributes to pancreatic islets p-cell dysfunction. As demonstrated in this study, 
hyperglycemia contributes to oxidative stress /damage by augmenting mitochondrial 
ROS production and probably leads to the progressive P-cell loss/cell death via 
1 2 1 
apoptosis. Oxidative stress and cell apoptosis have been well established associated 
with the signaling pathways involving the activities of INK, PERK, Akt, MAPK and 
c-myc. In addition, canonical Wnt signaling pathway is involved in pancreas 
development, pancreatic islets functions and insulin secretion/synthesis. Moreover, 
canonical Wnt signalling pathway has been suggested to be closely related to a 
family of transcription factors — FoxOs, which cause oxidative stress in normal / 
healthy pancreatic islets p-cells. However, the participation of Wnt signalling 
cascade in the development of pancreatic islets of obese/diabetic (db^/db^) mice as 
well as the beneficial effects offered by L-NAC treatment is unknown. Therefore, in 
the future study, the role(s) of Wnt signalling pathway in mediating the pancreatic 
islets protective effects of L-NAC administration will be evaluated in details which 
could be important in providing scientific evidence for the uses of L-NAC in treating 
T2DM. 
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